Date,Open,High,Low,Close,Volume,Dividends,Stock Splits,SMA_10,SMA_40,SMA_120,Close_10_%_D,10_40_%_D,40_120_%_D,RSI,earningsGrowth,revenueGrowth,profitMargins,grossMargins,returnOnEquity,debtToEquity,priceToBook,forwardPE,longName,sector,longBusinessSummary
2022-06-27,7.5,7.989999771118164,7.309999942779541,7.539999961853027,19416,0.0,0.0,,,,,,,,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-06-28,7.699999809265137,7.789999961853027,7.429999828338623,7.5,21747,0.0,0.0,,,,,,,0.0,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-06-29,7.5,7.699999809265137,7.420000076293945,7.5,17460,0.0,0.0,,,,,,,0.0,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-06-30,7.420000076293945,7.5,7.309999942779541,7.380000114440918,65646,0.0,0.0,,,,,,,0.0,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-07-01,7.5,7.679999828338623,7.239999771118164,7.409999847412109,12542,0.0,0.0,,,,,,,17.295457376532624,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-07-04,7.409999847412109,7.409999847412109,7.25,7.380000114440918,13984,0.0,0.0,,,,,,,14.579835183058464,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-07-05,7.28000020980835,7.389999866485596,7.199999809265137,7.300000190734863,39147,0.0,0.0,,,,,,,10.048721381613532,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-07-06,7.300000190734863,7.340000152587891,7.179999828338623,7.329999923706055,33351,0.0,0.0,,,,,,,20.079261991502946,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-07-07,7.329999923706055,7.329999923706055,7.179999828338623,7.269999980926514,17434,0.0,0.0,,,,,,,16.190615319407883,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-07-08,7.269999980926514,7.380000114440918,7.170000076293945,7.329999923706055,24635,0.0,0.0,7.394000005722046,,,-0.8655677842367216,,,30.65363900383167,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-07-11,7.329999923706055,7.380000114440918,7.179999828338623,7.340000152587891,29478,0.0,0.0,7.374000024795532,,,-0.4610777338393694,,,32.737102073888565,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-07-12,7.340000152587891,7.340000152587891,7.090000152587891,7.269999980926514,35739,0.0,0.0,7.351000022888184,,,-1.1018914665959345,,,26.69184727631277,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-07-13,7.269999980926514,7.309999942779541,7.099999904632568,7.210000038146973,20310,0.0,0.0,7.322000026702881,,,-1.5296365494052333,,,22.804668186066152,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-07-14,7.360000133514404,7.389999866485596,7.019999980926514,7.340000152587891,37842,0.0,0.0,7.318000030517578,,,0.30063025387492825,,,42.3832845731718,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-07-15,7.380000114440918,7.380000114440918,7.179999828338623,7.360000133514404,19166,0.0,0.0,7.313000059127807,,,0.642692110031277,,,44.70673660969689,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-07-18,7.389999866485596,7.389999866485596,7.150000095367432,7.25,16234,0.0,0.0,7.3000000476837155,,,-0.6849321555769091,,,36.08715518844362,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-07-19,7.480000019073486,7.480000019073486,7.059999942779541,7.25,81066,0.0,0.0,7.29500002861023,,,-0.6168612533755209,,,36.08715518844362,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-07-20,7.480000019073486,7.480000019073486,7.150000095367432,7.440000057220459,2565,0.0,0.0,7.30600004196167,,,1.8341091498654039,,,53.89440123876239,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-07-21,7.480000019073486,7.480000019073486,7.25,7.46999979019165,16689,0.0,0.0,7.326000022888183,,,1.9655987831501107,,,55.97989101411369,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-07-22,7.489999771118164,7.699999809265137,7.360000133514404,7.699999809265137,73141,0.0,0.0,7.363000011444091,,,4.5769359948018,,,67.94958850418564,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-07-25,7.699999809265137,8.0600004196167,7.480000019073486,7.5,23921,0.0,0.0,7.378999996185303,,,1.6397886417841228,,,54.15884077582177,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-07-26,7.699999809265137,7.949999809265137,7.599999904632568,7.619999885559082,7578,0.0,0.0,7.41399998664856,,,2.7785257523805704,,,59.47350640764608,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-07-27,7.860000133514404,7.980000019073486,7.599999904632568,7.760000228881836,39929,0.0,0.0,7.469000005722046,,,3.8961068809325567,,,64.62620730608619,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-07-28,7.980000019073486,7.980000019073486,7.619999885559082,7.78000020980835,9629,0.0,0.0,7.513000011444092,,,3.5538426455151444,,,65.3048632721518,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-07-29,7.769999980926514,7.800000190734863,7.599999904632568,7.800000190734863,20958,0.0,0.0,7.557000017166137,,,3.215564020335289,,,66.00719094889077,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-08-01,8.0,8.0,7.599999904632568,7.690000057220459,28260,0.0,0.0,7.601000022888184,,,1.1708990141333733,,,58.940249925030436,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-08-02,7.690000057220459,7.789999961853027,7.599999904632568,7.75,11546,0.0,0.0,7.651000022888184,,,1.2939482004398792,,,61.369713817465936,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-08-03,7.75,8.0,7.400000095367432,7.920000076293945,52483,0.0,0.0,7.699000024795533,,,2.870503322336097,,,67.27748638410173,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-08-04,7.920000076293945,7.920000076293945,7.610000133514404,7.639999866485596,28171,0.0,0.0,7.716000032424927,,,-0.9849684502327104,,,52.92178930818489,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-08-05,7.900000095367432,7.960000038146973,7.420000076293945,7.769999980926514,91301,0.0,0.0,7.7230000495910645,,,0.608570905524439,,,57.4603533497994,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-08-08,7.769999980926514,7.889999866485596,7.630000114440918,7.840000152587891,25757,0.0,0.0,7.757000064849853,,,1.0700024112948623,,,59.71256004309106,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-08-09,7.840000152587891,7.840000152587891,7.409999847412109,7.670000076293945,89946,0.0,0.0,7.76200008392334,,,-1.185261616009835,,,52.449929231432165,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-08-10,7.519999980926514,7.889999866485596,7.519999980926514,7.579999923706055,27976,0.0,0.0,7.744000053405761,,,-2.1177702552775743,,,49.048709609059905,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-08-11,7.570000171661377,7.869999885559082,7.519999980926514,7.699999809265137,59526,0.0,0.0,7.736000013351441,,,-0.4653594108605443,,,53.38883243821115,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-08-12,7.699999809265137,7.699999809265137,7.5,7.679999828338623,39999,0.0,0.0,7.723999977111816,,,-0.5696549573223334,,,52.58486031424466,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-08-15,7.900000095367432,7.900000095367432,7.449999809265137,7.690000057220459,33500,0.0,0.0,7.723999977111816,,,-0.44018539606561186,,,52.96624675241977,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-08-16,7.800000190734863,7.800000190734863,7.510000228881836,7.670000076293945,10524,0.0,0.0,7.715999984741211,,,-0.5961626300963345,,,52.06427617448995,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-08-17,7.670000076293945,7.670000076293945,7.320000171661377,7.630000114440918,43908,0.0,0.0,7.686999988555908,,,-0.7415100065025302,,,50.22221637155312,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-08-18,7.630000114440918,7.630000114440918,7.320000171661377,7.510000228881836,53232,0.0,0.0,7.674000024795532,,,-2.137083598954848,,,45.07039077809317,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-08-19,7.550000190734863,7.630000114440918,7.199999809265137,7.400000095367432,22928,0.0,0.0,7.637000036239624,7.5292500257492065,,-3.103312030215581,1.4310855679108077,,40.925991832545385,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-08-22,7.400000095367432,7.400000095367432,7.110000133514404,7.289999961853027,55435,0.0,0.0,7.582000017166138,7.523000025749207,,-3.85122731010292,0.7842614809914886,,37.238376184433655,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-08-23,7.289999961853027,7.369999885559082,7.199999809265137,7.210000038146973,19965,0.0,0.0,7.53600001335144,7.5157500267028805,,-4.325901998764564,0.2694340096013476,,34.78365223275995,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-08-24,7.480000019073486,7.610000133514404,7.119999885559082,7.199999809265137,15517,0.0,0.0,7.498000001907348,7.50825002193451,,-3.9743957397493466,-0.13651676485488726,,34.47769885796593,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-08-25,7.309999942779541,7.489999771118164,6.989999771118164,7.409999847412109,47373,0.0,0.0,7.469000005722046,7.509000015258789,,-0.7899338367216026,-0.5326942263345359,,45.348807320241455,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-08-26,7.409999847412109,7.590000152587891,7.199999809265137,7.389999866485596,24362,0.0,0.0,7.440000009536743,7.508500015735626,,-0.6720449326217263,-0.9122994746663979,,44.5900248433002,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-08-29,7.389999866485596,7.389999866485596,7.099999904632568,7.199999809265137,22416,0.0,0.0,7.390999984741211,7.504000008106232,,-2.5842264358056566,-1.5058638491864573,,38.07264149901971,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-08-30,7.199999809265137,7.880000114440918,7.119999885559082,7.880000114440918,157894,0.0,0.0,7.411999988555908,7.518500006198883,,6.314086975277926,-1.4165061854780492,,60.38795114069421,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-08-31,7.940000057220459,7.940000057220459,7.519999980926514,7.880000114440918,57137,0.0,0.0,7.436999988555908,7.532250010967255,,5.956704673479902,-1.2645626774557244,,60.38795114069421,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-09-01,8.0,8.0600004196167,7.53000020980835,7.900000095367432,45928,0.0,0.0,7.475999975204468,7.548000013828277,,5.671483702103238,-0.9538955815037331,,60.868936496178776,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-09-02,8.0,8.0,7.610000133514404,7.889999866485596,44131,0.0,0.0,7.524999952316284,7.562000012397766,,4.8504972289994575,-0.4892893417193994,,60.473538041547464,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-09-05,7.829999923706055,7.829999923706055,7.380000114440918,7.550000190734863,22827,0.0,0.0,7.550999975204467,7.56725001335144,,-0.013240424750194288,-0.2147416580435681,,48.85391860380404,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-09-06,7.519999980926514,7.630000114440918,7.309999942779541,7.429999828338623,42622,0.0,0.0,7.572999954223633,7.571250009536743,,-1.8882890102918246,0.02311302208599104,,45.52884047454392,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-09-07,7.619999885559082,7.619999885559082,7.059999942779541,7.309999942779541,78008,0.0,0.0,7.583999967575073,7.573750007152557,,-3.612869540704143,0.1353353413148804,,42.419615581996254,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-09-08,7.590000152587891,7.590000152587891,7.110000133514404,7.130000114440918,32783,0.0,0.0,7.555999994277954,7.568500006198883,,-5.637902066697188,-0.16515837894815796,,38.20496744977041,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-09-09,7.650000095367432,7.650000095367432,7.099999904632568,7.300000190734863,20127,0.0,0.0,7.5470000267028805,7.567000007629394,,-3.2728214534792586,-0.2643052848731172,,43.87650736244703,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-09-12,7.210000038146973,7.449999809265137,6.980000019073486,7.400000095367432,33673,0.0,0.0,7.567000055313111,7.5707500100135805,,-2.2069506901671203,-0.049532142727072646,,46.96028974647801,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-09-13,7.599999904632568,7.599999904632568,7.099999904632568,7.210000038146973,35163,0.0,0.0,7.500000047683716,7.569750010967255,,-3.866666769239634,-0.9214302081638547,,42.21419528734935,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-09-14,7.210000038146973,7.210000038146973,7.110000133514404,7.210000038146973,1460,0.0,0.0,7.4330000400543215,7.5640000104904175,,-3.0001345446746304,-1.731887496753223,,42.21419528734934,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-09-15,7.289999961853027,7.300000190734863,6.909999847412109,7.090000152587891,29186,0.0,0.0,7.352000045776367,7.554500019550323,,-3.5636546729755816,-2.6805211893560865,,39.30451970101602,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-09-16,7.0,7.739999771118164,7.0,7.400000095367432,55510,0.0,0.0,7.30300006866455,7.5470000267028805,,1.3282216320808407,-3.233072176692814,,49.07059602477985,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-09-19,7.190000057220459,7.429999828338623,7.0,7.070000171661377,28195,0.0,0.0,7.255000066757202,7.536250030994415,,-2.5499640715856744,-3.7319616928911983,,41.428687341918184,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-09-20,6.880000114440918,7.420000076293945,6.739999771118164,7.0,47490,0.0,0.0,7.21200008392334,7.520750033855438,,-2.939546331896486,-4.1053079618685375,,40.005474399649536,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-09-21,7.019999980926514,7.429999828338623,6.599999904632568,7.25,77438,0.0,0.0,7.206000089645386,7.5080000281333925,,0.6106010242469971,-4.022375297767397,,47.00728656728595,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-09-22,7.25,7.25,6.599999904632568,7.03000020980835,45113,0.0,0.0,7.196000099182129,7.489250028133393,,-2.30683556261549,-3.9156114143561696,,42.32592454803101,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-09-23,7.03000020980835,7.099999904632568,6.039999961853027,7.0,85163,0.0,0.0,7.166000080108643,7.469250023365021,,-2.316495649636192,-4.059978475854513,,41.715833463987394,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-09-26,7.010000228881836,7.070000171661377,6.300000190734863,7.0,169778,0.0,0.0,7.1260000705719,7.452000021934509,,-1.7681738608485251,-4.374663854039834,,41.715833463987394,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-09-27,7.0,7.050000190734863,6.690000057220459,6.900000095367432,20903,0.0,0.0,7.095000076293945,7.430750024318695,,-2.7484140779371384,-4.518385720498438,,39.51400281933422,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-09-28,6.900000095367432,7.010000228881836,6.710000038146973,6.820000171661377,28773,0.0,0.0,7.056000089645385,7.403250026702881,,-3.3446699969623883,-4.690506680241717,,37.79532019565291,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-09-29,6.78000020980835,6.880000114440918,6.510000228881836,6.550000190734863,26049,0.0,0.0,7.002000093460083,7.376000034809112,,-6.455297010741128,-5.070498096312825,,32.6359184840891,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-09-30,6.610000133514404,6.949999809265137,6.550000190734863,6.949999809265137,89516,0.0,0.0,6.957000064849853,7.355500030517578,,-0.10062175534660857,-5.4177141460725915,,44.68342395139521,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-10-03,6.849999904632568,6.940000057220459,6.360000133514404,6.789999961853027,8858,0.0,0.0,6.929000043869019,7.329250025749206,,-2.006062651695072,-5.460995060531768,,41.48726602535374,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-10-04,6.610000133514404,6.940000057220459,6.610000133514404,6.739999771118164,24489,0.0,0.0,6.903000020980835,7.306000018119812,,-2.361295804248177,-5.516014182035116,,40.51204571865907,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-10-05,6.690000057220459,6.940000057220459,6.400000095367432,6.78000020980835,5850,0.0,0.0,6.85600004196167,7.28600002527237,,-1.1085156313910194,-5.901729094416596,,41.69287556037771,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-10-06,6.989999771118164,6.989999771118164,6.559999942779541,6.800000190734863,9994,0.0,0.0,6.833000040054321,7.2635000348091125,,-0.48294817980412763,-5.926894647094269,,42.3094878701528,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-10-07,6.539999961853027,6.769999980926514,6.539999961853027,6.699999809265137,8480,0.0,0.0,6.803000020980835,7.239000034332276,,-1.5140410318688757,-6.022931499981094,,40.03002170075251,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-10-10,6.789999961853027,6.789999961853027,6.400000095367432,6.610000133514404,19467,0.0,0.0,6.764000034332275,7.212000036239624,,-2.2767578361355407,-6.211869102276641,,38.0434717195172,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-10-11,6.679999828338623,6.679999828338623,6.380000114440918,6.389999866485596,39007,0.0,0.0,6.713000011444092,7.180000030994416,,-4.811561811527733,-6.5041785171920825,,33.64769221246736,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-10-12,6.78000020980835,6.78000020980835,6.210000038146973,6.75,21223,0.0,0.0,6.7059999942779545,7.158000028133392,,0.6561289257320241,-6.314613468551586,,44.87269927614131,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-10-13,6.210000038146973,6.909999847412109,6.210000038146973,6.590000152587891,26799,0.0,0.0,6.709999990463257,7.135000026226043,,-1.7883731452446938,-5.956552686764096,,41.51145456579785,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-10-14,6.510000228881836,6.650000095367432,6.46999979019165,6.510000228881836,4063,0.0,0.0,6.666000032424927,7.1127500295639035,,-2.3402310648705815,-6.280974240372221,,39.90204072421738,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-10-17,6.510000228881836,6.889999866485596,6.340000152587891,6.889999866485596,14537,0.0,0.0,6.676000022888184,7.102750027179718,,3.205509929055254,-6.008236283953577,,49.84837561792721,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-10-18,6.889999866485596,6.889999866485596,6.5,6.829999923706055,41638,0.0,0.0,6.685000038146972,7.093250024318695,,2.169033429045053,-5.755471536630839,,48.48393832818641,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-10-19,6.800000190734863,6.800000190734863,6.440000057220459,6.519999980926514,28334,0.0,0.0,6.659000015258789,7.07625002861023,,-2.0874010213810323,-5.896484884853462,,42.075818769204496,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-10-20,6.519999980926514,6.739999771118164,5.980000019073486,6.460000038146973,54911,0.0,0.0,6.625,7.052500033378601,,-2.4905654619324884,-6.061680699826972,,40.94774724723295,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-10-21,6.599999904632568,6.599999904632568,6.289999961853027,6.570000171661377,4329,0.0,0.0,6.612000036239624,7.032000041007995,,-0.6352066598313731,-5.972696278712862,,43.9164493513065,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-10-24,6.5,6.5,6.349999904632568,6.400000095367432,9326,0.0,0.0,6.591000032424927,7.012000048160553,,-2.8978900943385915,-6.003993337764832,,40.52565982992502,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-10-25,6.400000095367432,6.400000095367432,6.199999809265137,6.349999904632568,19993,0.0,0.0,6.587000036239624,6.973750042915344,,-3.5979980310179904,-5.545796799365075,,39.5582338764925,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-10-26,6.349999904632568,6.400000095367432,6.039999961853027,6.190000057220459,39614,0.0,0.0,6.53100004196167,6.931500041484833,,-5.221252220950645,-5.77797009487386,,36.55130524414969,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-10-27,6.179999828338623,6.489999771118164,6.0,6.150000095367432,27744,0.0,0.0,6.487000036239624,6.887750041484833,,-5.195004454902762,-5.818300647257766,,35.818285434005375,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-10-28,6.099999904632568,6.230000019073486,6.090000152587891,6.150000095367432,21516,0.0,0.0,6.451000022888183,6.844250047206879,,-4.665942124520266,-5.7456992600552335,,35.818285434005375,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-10-31,6.650000095367432,6.650000095367432,6.0,6.480000019073486,64729,0.0,0.0,6.410000038146973,6.817500042915344,,1.0920433776900467,-5.977264425422921,,46.1509932297941,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-11-01,6.480000019073486,6.480000019073486,6.170000076293945,6.179999828338623,7585,0.0,0.0,6.3450000286102295,6.786250042915344,,-2.6004759578818644,-6.502118423499106,,39.867336777653435,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-11-02,6.119999885559082,6.179999828338623,5.800000190734863,6.050000190734863,70895,0.0,0.0,6.298000049591065,6.754750049114227,,-3.937755746323061,-6.761908230535599,,37.48556195187926,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-11-03,6.0,6.5,5.989999771118164,6.170000076293945,43386,0.0,0.0,6.269000053405762,6.730750048160553,,-1.5791988557733807,-6.860305188141451,,40.99010722634055,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-11-04,5.989999771118164,6.070000171661377,5.75,5.900000095367432,146418,0.0,0.0,6.2020000457763675,6.695750045776367,,-4.869396133181284,-7.3740805230842446,,36.08801057540591,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-11-07,5.900000095367432,6.239999771118164,5.5,6.0,118439,0.0,0.0,6.162000036239624,6.660750043392182,,-2.6290171257201846,-7.487895565865656,,38.99784660488484,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-11-08,6.0,6.179999828338623,5.980000019073486,6.099999904632568,59402,0.0,0.0,6.137000036239624,6.633000040054322,,-0.6029025808793582,-7.477762713998648,,41.849046737413296,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-11-09,6.0,6.400000095367432,5.949999809265137,6.349999904632568,86745,0.0,0.0,6.153000020980835,6.611500036716461,,3.201688330570325,-6.934886382657206,,48.34868285811816,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-11-10,6.300000190734863,6.489999771118164,5.980000019073486,6.420000076293945,35706,0.0,0.0,6.1800000190734865,6.594750034809112,,3.88349605954273,-6.289093802592186,,50.03275761775552,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-11-11,6.449999809265137,6.449999809265137,6.050000190734863,6.150000095367432,37119,0.0,0.0,6.1800000190734865,6.563500034809112,,-0.48543565717581494,-5.8429193829779456,,44.06485626604738,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-11-14,6.300000190734863,6.300000190734863,5.980000019073486,6.079999923706055,6782,0.0,0.0,6.1400000095367435,6.538750028610229,,-0.9772000934445564,-6.098260635882383,,42.64464879639355,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-11-15,5.980000019073486,6.389999866485596,5.849999904632568,6.099999904632568,21734,0.0,0.0,6.1320000171661375,6.516250026226044,,-0.5218544103716065,-5.89679658566522,,43.207849140258325,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-11-16,6.090000152587891,6.090000152587891,5.949999809265137,6.010000228881836,9826,0.0,0.0,6.128000020980835,6.485250031948089,,-1.9255840681298204,-5.508654395857437,,41.2451320119441,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-11-17,6.389999866485596,6.389999866485596,6.03000020980835,6.03000020980835,7214,0.0,0.0,6.114000034332276,6.46025003194809,,-1.3738930986626954,-5.359699638612941,,41.876985684047405,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-11-18,6.03000020980835,6.300000190734863,5.920000076293945,6.099999904632568,10413,0.0,0.0,6.134000015258789,6.437750029563904,,-0.5542893795507504,-4.7182635689520644,,44.1411898645949,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-11-21,6.099999904632568,6.099999904632568,5.599999904632568,5.699999809265137,84363,0.0,0.0,6.103999996185303,6.405250024795532,,-6.618613813444404,-4.703173606714061,,35.60558636725422,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-11-22,5.849999904632568,5.989999771118164,5.699999809265137,5.949999809265137,32273,0.0,0.0,6.08899998664856,6.381500017642975,,-2.28280797648564,-4.583562331516708,,43.02151726606439,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-11-23,5.809999942779541,6.050000190734863,5.760000228881836,6.050000190734863,19716,0.0,0.0,6.059000015258789,6.362250018119812,,-0.1485364664344102,-4.766395567564318,,45.71458321922219,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-11-24,6.050000190734863,6.190000057220459,5.789999961853027,6.010000228881836,39332,0.0,0.0,6.0180000305175785,6.348750019073487,,-0.13293123288758973,-5.20968675034045,,44.80240429504021,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-11-25,6.010000228881836,6.010000228881836,5.800000190734863,5.800000190734863,20622,0.0,0.0,5.983000040054321,6.320000028610229,,-3.05866368200453,-5.332278275796374,,40.260397239391686,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-11-28,6.0,6.0,5.710000038146973,5.889999866485596,48383,0.0,0.0,5.964000034332275,6.297500026226044,,-1.2407808085293632,-5.2957521318761795,,42.930669334079234,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-11-29,5.840000152587891,5.889999866485596,5.699999809265137,5.699999809265137,43300,0.0,0.0,5.924000024795532,6.271500027179718,,-3.78123252182341,-5.540939183260366,,38.970393396223265,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-11-30,5.650000095367432,6.199999809265137,5.639999866485596,6.119999885559082,104837,0.0,0.0,5.934999990463257,6.255000019073487,,3.1171001751153367,-5.115907715978387,,49.95944527693667,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-12-01,6.119999885559082,6.460000038146973,5.900000095367432,6.170000076293945,37170,0.0,0.0,5.948999977111816,6.239250016212464,,3.714911750418643,-4.652002057081274,,51.088557476583844,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-12-02,6.170000076293945,6.170000076293945,5.869999885559082,5.940000057220459,50952,0.0,0.0,5.932999992370606,6.220250022411347,,0.11798524960146166,-4.617982058691996,,45.95212611562629,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-12-05,5.949999809265137,6.639999866485596,5.940000057220459,6.150000095367432,23452,0.0,0.0,5.978000020980835,6.208750021457672,,2.87721769459573,-3.7165290868428755,,50.81452826497039,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-12-06,6.139999866485596,6.489999771118164,6.0,6.25,43667,0.0,0.0,6.008000040054322,6.205250024795532,,4.027962022841304,-3.178759662431332,,52.98366021891277,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-12-07,6.25,6.25,5.829999923706055,5.829999923706055,38401,0.0,0.0,5.986000013351441,6.182250022888184,,-2.6060823471005077,-3.1744107535311263,,44.1724580701506,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-12-08,5.699999809265137,6.090000152587891,5.690000057220459,5.869999885559082,50451,0.0,0.0,5.971999979019165,6.164250016212463,,-1.7079721001076602,-3.1187903911695005,,45.10870747910028,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-12-09,6.03000020980835,6.03000020980835,5.75,5.929999828338623,22797,0.0,0.0,5.984999942779541,6.149750006198883,6.930583353837331,-0.9189659977736735,-2.6789717184158066,-11.266488082942045,46.55652452494913,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-12-12,5.71999979019165,5.980000019073486,5.420000076293945,5.800000190734863,47178,0.0,0.0,5.975999975204468,6.122500014305115,6.9160833557446795,-2.9451101941074396,-2.3928140262695305,-11.474461781615073,43.85736383231488,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-12-13,5.800000190734863,5.989999771118164,5.75,5.989999771118164,14582,0.0,0.0,6.00499997138977,6.101500010490417,6.903500020503998,-0.2497951764042142,-1.5815789385353232,-11.61729568525488,48.552098347631706,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-12-14,5.650000095367432,5.980000019073486,5.650000095367432,5.829999923706055,35004,0.0,0.0,5.975999975204468,6.084250009059906,6.889583353201548,-2.443106628249577,-1.7791845123761367,-11.689144362661768,45.129687282278915,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-12-15,5.760000228881836,6.840000152587891,5.760000228881836,5.900000095367432,31785,0.0,0.0,5.948999977111816,6.070250010490417,6.877250019709269,-0.8236658586805609,-1.9974471095763855,-11.734341588659696,46.89343552649171,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-12-16,5.980000019073486,5.980000019073486,5.550000190734863,5.599999904632568,77677,0.0,0.0,5.914999961853027,6.046000003814697,6.862166686852773,-5.325444788705917,-2.16672249220999,-11.893716959714338,40.83526314421214,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-12-19,5.619999885559082,5.840000152587891,5.590000152587891,5.730000019073486,44327,0.0,0.0,5.872999954223633,6.029250001907348,6.848416686058044,-2.4348703603736,-2.591533733620037,-11.961402492029283,44.19941224744509,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-12-20,5.909999847412109,5.909999847412109,5.360000133514404,5.699999809265137,12951,0.0,0.0,5.817999935150146,6.012999999523163,6.835083349545797,-2.028190567210176,-3.2429746281137573,-12.027407830765705,43.58352684511123,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-12-21,6.170000076293945,6.170000076293945,5.760000228881836,5.980000019073486,2029,0.0,0.0,5.83299994468689,6.007749998569489,6.823833350340525,2.520145307398722,-2.908743771365472,-11.959309524027455,50.514302770007255,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-12-22,6.130000114440918,6.130000114440918,5.400000095367432,5.78000020980835,36597,0.0,0.0,5.823999977111816,5.998500001430512,6.811416685581207,-0.7554905129873712,-2.909061003202153,-11.934619796077426,46.15285748887475,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-12-23,5.670000076293945,6.150000095367432,5.5,5.849999904632568,63031,0.0,0.0,5.815999984741211,5.99099999666214,6.799083352088928,0.5845928469834802,-2.921048439633274,-11.88518089248774,47.85001254390049,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-12-27,5.849999904632568,5.980000019073486,5.5,5.699999809265137,36851,0.0,0.0,5.8059999465942385,5.971499991416931,6.785416682561238,-1.8256999363439663,-2.7714987031829943,-11.995087836478808,44.605653998881266,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-12-28,5.599999904632568,5.96999979019165,5.449999809265137,5.889999866485596,55580,0.0,0.0,5.795999956130982,5.964249992370606,6.773916681607564,1.621806609145699,-2.82097558712072,-11.95271107238967,49.29531802754826,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-12-29,5.840000152587891,5.900000095367432,5.570000171661377,5.900000095367432,130643,0.0,0.0,5.802999973297119,5.9604999899864195,6.7630000154177345,1.67155130995459,-2.6423960566042917,-11.866036131921351,49.5374689970815,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2022-12-30,5.989999771118164,6.059999942779541,5.699999809265137,6.059999942779541,38921,0.0,0.0,5.81899995803833,5.95774998664856,6.752333347002665,4.141604854426832,-2.328899818239626,-11.76753752400002,53.374178825156775,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-01-02,6.050000190734863,6.25,6.039999961853027,6.210000038146973,15943,0.0,0.0,5.87999997138977,5.965499985218048,6.742750012874604,5.61224606059318,-1.4332413718906851,-11.52719626521041,56.69811998758831,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-01-03,6.210000038146973,6.599999904632568,6.010000228881836,6.239999771118164,37748,0.0,0.0,5.9309999465942385,5.971499979496002,6.734333344300588,5.2099110994152475,-0.6782221056824314,-11.327526063885573,57.35294671911354,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-01-04,6.389999866485596,6.75,6.159999847412109,6.349999904632568,22620,0.0,0.0,5.995999956130982,5.977749979496002,6.726833343505859,5.903935141620829,0.30529842662504025,-11.135750296728085,59.756093436913126,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-01-05,6.869999885559082,6.869999885559082,6.099999904632568,6.690000057220459,65315,0.0,0.0,6.0669999599456785,5.9862499833106995,6.72058334350586,10.268668227918672,1.3489242323675938,-10.926631255972014,66.11237310612924,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-01-09,6.690000057220459,7.690000057220459,6.510000228881836,7.179999828338623,108835,0.0,0.0,6.206999921798706,6.005249977111816,6.718166677157084,15.675848538724551,3.359559476388695,-10.611774525769158,72.78396125507373,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-01-10,6.900000095367432,7.25,6.900000095367432,7.170000076293945,56285,0.0,0.0,6.338999938964844,6.030749976634979,6.713750012715658,13.10932552974284,5.111303959277402,-10.17315263134754,72.47039685588626,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-01-11,7.170000076293945,7.170000076293945,6.820000171661377,6.900000095367432,39303,0.0,0.0,6.458999967575073,6.051249980926514,6.708750013510386,6.827684316554117,6.738277016050957,-9.80063396697997,64.40262158713445,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-01-12,7.119999885559082,7.190000057220459,6.619999885559082,6.860000133514404,44610,0.0,0.0,6.555999994277954,6.07024998664856,6.7024166822433475,4.636975892339538,8.002141735477048,-9.431921731598415,63.27871216610893,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-01-13,6.880000114440918,6.880000114440918,6.400000095367432,6.699999809265137,45215,0.0,0.0,6.635999965667724,6.087499976158142,6.693583345413208,0.9644340555835511,9.01026680341351,-9.054692202650848,58.85433453496128,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-01-16,6.409999847412109,6.800000190734863,6.409999847412109,6.650000095367432,35985,0.0,0.0,6.6949999809265135,6.102999973297119,6.684166677792867,-0.6721416831558283,9.700147635910428,-8.69467702573287,57.50131620050861,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-01-17,6.650000095367432,7.190000057220459,6.429999828338623,6.610000133514404,56937,0.0,0.0,6.7349999904632565,6.115749979019165,6.674250010649363,-1.8559741221358825,10.125495868348192,-8.367981881695483,56.38455043675091,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-01-18,6.619999885559082,7.099999904632568,6.559999942779541,6.789999961853027,26087,0.0,0.0,6.790000009536743,6.142999982833862,6.666750009854635,-7.022638523667705e-07,10.532313666138247,-7.8561521917962684,60.13649951193209,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-01-19,6.610000133514404,6.940000057220459,6.550000190734863,6.800000190734863,23927,0.0,0.0,6.835000038146973,6.164249992370605,6.658833344777425,-0.5120679914670218,10.881292072945522,-7.42747755948458,60.34061926905601,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-01-20,6.800000190734863,6.960000038146973,6.650000095367432,6.75,22465,0.0,0.0,6.841000032424927,6.181749987602234,6.649083344141642,-1.3302153485397687,10.664456604438026,-7.028538105950583,58.7215931877472,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-01-23,6.96999979019165,6.96999979019165,6.5,6.550000190734863,31103,0.0,0.0,6.778000068664551,6.19524998664856,6.640000013510386,-3.3638223018579847,9.406401408690227,-6.698042559591793,52.63767476420012,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-01-24,6.539999961853027,6.539999961853027,6.0,6.309999942779541,36081,0.0,0.0,6.692000055313111,6.207999980449676,6.627833346525828,-5.708310062404749,7.79639298304856,-6.334398348990172,46.4221526018596,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-01-25,6.099999904632568,6.789999961853027,5.96999979019165,6.489999771118164,25161,0.0,0.0,6.651000022888184,6.2229999780654905,6.616583343346914,-2.4206923953686217,6.877712459123984,-5.9484381115999705,51.08712616659734,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-01-26,6.980000019073486,6.980000019073486,6.489999771118164,6.570000171661377,9813,0.0,0.0,6.622000026702881,6.244749987125397,6.607416677474975,-0.7852590581669727,6.041075148808968,-5.488781895440737,53.04398679769858,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-01-27,6.579999923706055,6.579999923706055,6.389999866485596,6.480000019073486,23089,0.0,0.0,6.600000047683716,6.253749990463257,6.598250011603038,-1.8181822385341364,5.53667891662567,-5.2210816585303155,50.59180503496724,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-01-30,6.480000019073486,6.5,5.989999771118164,6.239999771118164,36613,0.0,0.0,6.559000015258789,6.255499982833863,6.586083344618479,-4.863549983206376,4.851731008836723,-5.019422690038346,44.662393167010634,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-01-31,6.239999771118164,6.440000057220459,6.0,6.260000228881836,36844,0.0,0.0,6.524000024795532,6.263499987125397,6.574250014623006,-4.046594036025772,4.159017134279427,-4.726775325039548,45.238390636340256,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-02-01,6.260000228881836,6.389999866485596,6.0,6.179999828338623,41135,0.0,0.0,6.463000011444092,6.2642499804496765,6.561666679382324,-4.378774293739099,3.1727665979918043,-4.532639548229001,43.29707706952972,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-02-02,6.099999904632568,6.980000019073486,6.010000228881836,6.170000076293945,9099,0.0,0.0,6.4,6.262249982357025,6.549166679382324,-3.59374880790711,2.1996888982564755,-4.380964954343773,43.04840479924025,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-02-03,6.170000076293945,6.190000057220459,5.900000095367432,6.079999923706055,12446,0.0,0.0,6.332999992370605,6.268499982357025,6.5362500111262,-3.9949481915259906,1.028954457926428,-4.096385975343704,40.77834610648075,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-02-06,6.0,6.760000228881836,5.869999885559082,6.300000190734863,21093,0.0,0.0,6.307999992370606,6.27924998998642,6.526166677474976,-0.1268199373084676,0.4578572668715801,-3.7834873010642984,47.99724590290003,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-02-07,6.300000190734863,6.71999979019165,5.900000095367432,6.090000152587891,38062,0.0,0.0,6.28600001335144,6.283249998092652,6.515250011285146,-3.1180378674394977,0.04376740157758332,-3.5608766016752127,42.652622930129176,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-02-08,6.090000152587891,6.090000152587891,5.900000095367432,5.940000057220459,33054,0.0,0.0,6.23100004196167,6.286749994754791,6.504000012079874,-4.670197123760518,-0.8867849499285809,-3.3402524126935,39.28742105528525,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-02-09,5.980000019073486,6.289999961853027,5.909999847412109,6.170000076293945,18134,0.0,0.0,6.191000032424927,6.291250002384186,6.495333345731099,-0.3392013571473991,-1.5934825340157808,-3.141999532341819,46.28548715722856,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-02-10,6.170000076293945,6.170000076293945,5.789999961853027,6.059999942779541,17008,0.0,0.0,6.149000024795532,6.297000002861023,6.4858333468437195,-1.4473911474565382,-2.350325202449546,-2.911473882914223,43.69162112559968,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-02-13,6.119999885559082,6.119999885559082,5.809999942779541,5.989999771118164,34115,0.0,0.0,6.124000024795532,6.299249994754791,6.474000012874603,-2.1881164783607647,-2.782076756839059,-2.6992588472705124,42.075683982705186,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-02-14,5.800000190734863,6.070000171661377,5.71999979019165,6.050000190734863,15012,0.0,0.0,6.103000020980835,6.310500001907348,6.462833348910014,-0.8684225801043588,-3.2881702062244957,-2.3570675395545675,43.98794715157754,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-02-15,5.980000019073486,6.070000171661377,5.909999847412109,5.909999847412109,31283,0.0,0.0,6.076000022888183,6.314999997615814,6.452083349227905,-2.7320634438899662,-3.7846393478679907,-2.124637023303415,40.61841779167552,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-02-16,6.070000171661377,6.070000171661377,5.800000190734863,6.039999961853027,10789,0.0,0.0,6.063000011444092,6.323500001430512,6.436750014623006,-0.3793509739015504,-4.119553885150463,-1.7594284838655025,44.84346750444253,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-02-17,6.079999923706055,6.579999923706055,5.460000038146973,6.059999942779541,36093,0.0,0.0,6.061000013351441,6.325499999523163,6.421583346525828,-0.016500091894023582,-4.181487411140001,-1.4962563252355432,45.48609292046365,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-02-20,6.079999923706055,6.570000171661377,5.71999979019165,5.760000228881836,68824,0.0,0.0,6.0070000171661375,6.325,6.403750014305115,-4.1118659493666225,-5.027667712788342,-1.2297484150567686,38.281271245883694,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-02-21,6.070000171661377,6.070000171661377,5.75,5.860000133514404,24052,0.0,0.0,5.984000015258789,6.3252500057220455,6.3868333498636884,-2.0721905318882587,-5.3950435185099375,-0.9642234385676786,41.601801781975766,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-02-22,5.880000114440918,5.889999866485596,5.659999847412109,5.889999866485596,9681,0.0,0.0,5.978999996185303,6.330000007152558,6.373000013828277,-1.4885454048585196,-5.5450238636752545,-0.6747215845350276,42.59952138790822,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-02-23,5.900000095367432,5.900000095367432,5.630000114440918,5.869999885559082,22561,0.0,0.0,5.948999977111816,6.329500007629394,6.360000014305115,-1.3279558220991594,-6.0115337713711146,-0.47955985231318876,42.08332380317981,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-02-24,5.869999885559082,6.139999866485596,5.829999923706055,5.980000019073486,33915,0.0,0.0,5.940999984741211,6.331500005722046,6.348916681607564,0.6564557218051268,-6.167575150089609,-0.27432516063682444,45.961794221416035,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-02-27,5.909999847412109,5.940000057220459,5.760000228881836,5.909999847412109,34784,0.0,0.0,5.932999992370606,6.32775000333786,6.338750012715658,-0.3876646719715644,-6.238394544016831,-0.17353593935290046,43.94502082401107,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-02-28,5.599999904632568,6.039999961853027,5.599999904632568,5.800000190734863,8466,0.0,0.0,5.9079999923706055,6.3175000071525576,6.326250012715658,-1.828026434922301,-6.4819946864792035,-0.1383126741041355,40.90736513982192,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-03-01,5.980000019073486,5.980000019073486,5.710000038146973,5.789999961853027,14438,0.0,0.0,5.896000003814697,6.306250011920929,6.3128333449363705,-1.7978297471690603,-6.5054510577716,-0.10428491702101557,40.63238301830741,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-03-02,5.730000019073486,5.889999866485596,5.699999809265137,5.800000190734863,15478,0.0,0.0,5.872000026702881,6.292500019073486,6.301083346207936,-1.226155239111012,-6.682558460008085,-0.13621986351942994,41.059065343131834,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-03-03,6.0,6.170000076293945,5.800000190734863,5.820000171661377,25793,0.0,0.0,5.8480000495910645,6.270750021934509,6.289500013987223,-0.4787940781848225,-6.741617364186163,-0.2981157804438541,41.95753865544243,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-03-06,5.820000171661377,6.269999980926514,5.800000190734863,5.900000095367432,38519,0.0,0.0,5.862000036239624,6.238750028610229,6.27958334684372,0.6482439251601269,-6.038869815954654,-0.6502552156428375,45.53403697109539,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-03-07,6.070000171661377,6.989999771118164,5.920000076293945,6.099999904632568,57697,0.0,0.0,5.88600001335144,6.212000024318695,6.268750011920929,3.63574398225797,-5.247907432244568,-0.9052839480648526,53.28404461842417,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-03-08,5.900000095367432,6.309999942779541,5.889999866485596,6.110000133514404,8244,0.0,0.0,5.908000040054321,6.19225002527237,6.2607500116030375,3.4190943143295223,-4.590415181201369,-1.0941178964775304,53.63926047255319,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-03-09,6.110000133514404,6.110000133514404,5.880000114440918,6.0,8772,0.0,0.0,5.921000051498413,6.170750021934509,6.252416678269705,1.3342332007174154,-4.047319524342044,-1.3061614498443146,49.2070311285583,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-03-10,5.900000095367432,6.079999923706055,5.71999979019165,5.989999771118164,18901,0.0,0.0,5.9220000267028805,6.153000020980835,6.241916676362355,1.1482564016998653,-3.754266105806573,-1.4245088486720798,48.81214782424181,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-03-13,5.900000095367432,6.090000152587891,5.699999809265137,5.699999809265137,29992,0.0,0.0,5.901000022888184,6.129250013828278,6.230833339691162,-3.4062059454910725,-3.7239464930478716,-1.6303328997067843,39.03038499920218,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-03-14,5.699999809265137,6.0,5.699999809265137,5.929999828338623,10355,0.0,0.0,5.91399998664856,6.112250006198883,6.221916671593984,0.2705417944907766,-3.2434867577285456,-1.7625865337570674,47.940859274285685,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-03-15,5.909999847412109,6.0,5.710000038146973,5.989999771118164,10806,0.0,0.0,5.933999967575073,6.092250001430512,6.213500003019969,0.9437108838740851,-2.5975630320206786,-1.9513961781689186,49.99399280016738,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-03-16,5.989999771118164,5.989999771118164,5.650000095367432,5.829999923706055,19429,0.0,0.0,5.936999940872193,6.067999994754791,6.20458333492279,-1.8022573392584351,-2.1588670731020976,-2.201329771803268,44.90777290155459,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-03-17,5.820000171661377,6.0,5.739999771118164,5.980000019073486,51235,0.0,0.0,5.952999925613403,6.048749995231629,6.197583333651225,0.45355440613920794,-1.5829728405655326,-2.401473774648108,50.039469810086,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-03-20,6.190000057220459,6.190000057220459,5.599999904632568,6.0,88553,0.0,0.0,5.96299991607666,6.034999990463257,6.1929999987284345,0.6204944565500565,-1.1930418309921247,-2.5512676941323815,50.69887180427463,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-03-21,6.0,6.099999904632568,5.809999942779541,6.050000190734863,5322,0.0,0.0,5.95799994468689,6.0284999966621395,6.185500001907348,1.5441464736839388,-1.169445998412281,-2.538194247785895,52.39064552152046,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-03-22,6.0,6.239999771118164,5.800000190734863,6.050000190734863,8202,0.0,0.0,5.951999950408935,6.017500007152558,6.179333337148031,1.64650942779653,-1.0884928403118783,-2.618944814363499,52.39064552152046,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-03-23,5.989999771118164,5.989999771118164,5.610000133514404,5.760000228881836,45294,0.0,0.0,5.927999973297119,5.997250008583069,6.171166674296061,-2.834003798448783,-1.1546964890048128,-2.8182137169845762,42.565503488814095,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-03-24,6.079999923706055,6.079999923706055,5.75,5.980000019073486,29177,0.0,0.0,5.9269999980926515,5.9847500085830685,6.164500006039938,0.8942132781827323,-0.9649527617293019,-2.9158893224227653,50.19608415112887,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-03-27,6.0,6.489999771118164,5.829999923706055,6.050000190734863,8404,0.0,0.0,5.962000036239624,5.980000019073486,6.158250006039937,1.4760173425081478,-0.30100305646237746,-2.8944909153026503,52.36466450697646,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-03-28,5.650000095367432,6.5,5.650000095367432,5.900000095367432,19463,0.0,0.0,5.959000062942505,5.971000015735626,6.151583341757457,-0.990098455309291,-0.20097057044878885,-2.9355584731497633,47.583381565422634,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-03-29,6.0,6.289999961853027,5.699999809265137,5.789999961853027,25370,0.0,0.0,5.939000082015991,5.9612500190734865,6.144750006993612,-2.508841860672041,-0.3732428095836393,-2.9862889086012627,44.38294931482875,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-03-30,5.789999961853027,6.179999828338623,5.650000095367432,6.090000152587891,7542,0.0,0.0,5.965000104904175,5.959250020980835,6.142250009377798,2.0955581808111923,0.09649006004271979,-2.979364046034667,53.55744925062259,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-03-31,6.289999961853027,6.289999961853027,5.809999942779541,6.090000152587891,8953,0.0,0.0,5.976000118255615,5.959500026702881,6.136750010649363,1.9076310588419465,0.27687039984565226,-2.888336393675689,53.55744925062259,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-04-03,6.0,6.0,5.71999979019165,5.920000076293945,20128,0.0,0.0,5.96800012588501,5.9500000238418576,6.131166676680247,-0.8042903582202351,0.30252272220210674,-2.9548479496969633,48.31914586354176,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-04-04,5.920000076293945,6.0,5.71999979019165,5.880000114440918,35642,0.0,0.0,5.951000118255616,5.944750022888184,6.125916675726573,-1.1930768342096667,0.10513638661622454,-2.957380297976406,47.15058065350877,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-04-05,5.800000190734863,6.099999904632568,5.78000020980835,5.800000190734863,12935,0.0,0.0,5.926000118255615,5.941250026226044,6.1168333450953165,-2.126222156705617,-0.25667844145780544,-2.870493750006471,44.81614003382158,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-04-06,5.739999771118164,6.079999923706055,5.639999866485596,6.0,17282,0.0,0.0,5.9500000953674315,5.937000024318695,6.109916679064432,0.8403345181708082,0.2189670034611193,-2.8300984093323995,51.306799162762296,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-04-11,6.0,6.0,5.679999828338623,5.800000190734863,78691,0.0,0.0,5.9320001125335695,5.930500030517578,6.103916680812835,-2.225217789861585,0.025294359805617783,-2.8410717145005977,45.53859012171747,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-04-12,5.679999828338623,6.019999980926514,5.440000057220459,5.699999809265137,75138,0.0,0.0,5.897000074386597,5.923250031471253,6.097583345572153,-3.34068615629027,-0.44316814156392814,-2.8590558623113416,42.93917001705893,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-04-13,5.659999847412109,5.699999809265137,5.5,5.659999847412109,17654,0.0,0.0,5.873000049591065,5.913500022888184,6.090000009536743,-3.626769970720272,-0.6848731401093082,-2.898193536488765,41.90868071820407,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-04-14,5.659999847412109,6.0,5.5,5.699999809265137,46513,0.0,0.0,5.864000034332276,5.908250021934509,6.084166673819224,-2.7967296061895963,-0.748952522962882,-2.8913844954593695,43.37221893770375,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-04-17,5.699999809265137,5.800000190734863,5.539999961853027,5.800000190734863,7032,0.0,0.0,5.835000038146973,5.902250027656555,6.079583342870077,-0.5998260014274879,-1.1393958099786443,-2.9168662589598715,46.96927460828597,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-04-18,5.980000019073486,5.980000019073486,5.539999961853027,5.71999979019165,47721,0.0,0.0,5.798000001907349,5.893750023841858,6.07566667397817,-1.3452951309078842,-1.6246026985734656,-2.9941841759597114,44.53220995364704,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-04-19,5.980000019073486,5.980000019073486,5.599999904632568,5.599999904632568,33849,0.0,0.0,5.765999984741211,5.889750015735626,6.071083339055379,-2.8789469397838223,-2.10110837749977,-2.9868363386355194,41.08835167523453,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-04-20,5.679999828338623,5.760000228881836,5.400000095367432,5.460000038146973,47263,0.0,0.0,5.723999977111816,5.87975001335144,6.065333338578542,-4.612158281280276,-2.648922758381813,-3.0597382677502507,37.449620915754465,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-04-21,5.5,5.679999828338623,5.480000019073486,5.679999828338623,9079,0.0,0.0,5.711999940872192,5.874500012397766,6.058666670322419,-0.5602260655605489,-2.7661940792003965,-3.03972256514406,45.602148525322406,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-04-24,5.659999847412109,6.039999961853027,5.480000019073486,5.699999809265137,7592,0.0,0.0,5.681999921798706,5.870250010490418,6.054666670163472,0.31678788655689705,-3.2068495950819784,-3.0458598254769886,46.28752547003698,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-04-25,5.980000019073486,5.980000019073486,5.5,5.579999923706055,57486,0.0,0.0,5.659999895095825,5.860250008106232,6.050750001271566,-1.413427082553257,-3.417091638298869,-3.148369923154987,42.8028943176648,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-04-26,5.579999923706055,5.860000133514404,5.420000076293945,5.619999885559082,45891,0.0,0.0,5.65199990272522,5.853000009059906,6.046166666348776,-0.5661715802703473,-3.4341381517778364,-3.1948616032035524,44.30793959395281,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-04-27,5.619999885559082,5.960000038146973,5.28000020980835,5.440000057220459,29113,0.0,0.0,5.6299999237060545,5.844000005722046,6.042333332697551,-3.3747756493844587,-3.6618768276258975,-3.2823963203460016,39.29686759443952,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-04-28,5.599999904632568,5.599999904632568,5.320000171661377,5.460000038146973,21193,0.0,0.0,5.605999946594238,5.835750007629395,6.037833333015442,-2.6043508711762224,-3.936941451138102,-3.3469510375689957,40.107389035516036,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-05-02,5.519999980926514,5.760000228881836,5.139999866485596,5.420000076293945,38506,0.0,0.0,5.567999935150146,5.826250004768371,6.032166667779287,-2.6580434730592337,-4.432526400461119,-3.4136434609941397,38.98619962553856,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-05-03,5.940000057220459,5.940000057220459,5.199999809265137,5.260000228881836,43635,0.0,0.0,5.521999979019165,5.812250006198883,6.023083337148031,-4.744653225874634,-4.9937636349117795,-3.50042194582981,34.796052704400424,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-05-04,5.360000133514404,5.380000114440918,5.139999866485596,5.380000114440918,17902,0.0,0.0,5.5,5.79925000667572,6.014416670799255,-2.1818161010742188,-5.16015012857254,-3.5775150924975962,40.004220810802934,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-05-05,5.380000114440918,6.059999942779541,5.179999828338623,5.5,54367,0.0,0.0,5.503999996185303,5.784250009059906,6.00900000333786,-0.07267434934729039,-4.845053592698205,-3.740222901532882,44.75624839794023,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-05-08,5.519999980926514,5.699999809265137,5.239999771118164,5.380000114440918,32815,0.0,0.0,5.474000024795532,5.7660000085830685,6.003166671593984,-1.717206977143286,-5.064168979411644,-3.9506926258294652,41.238641616370955,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-05-09,5.360000133514404,5.599999904632568,5.300000190734863,5.380000114440918,32284,0.0,0.0,5.442000055313111,5.750500011444092,5.997166673342387,-1.1392859287397694,-5.364750117677315,-4.113053302232492,41.238641616370955,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-05-10,5.380000114440918,5.579999923706055,5.199999809265137,5.400000095367432,33033,0.0,0.0,5.424000072479248,5.7357500195503235,5.992083338896434,-0.442477448213715,-5.435208054892122,-4.277866392180708,42.11797876127224,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-05-11,5.400000095367432,5.5,5.28000020980835,5.380000114440918,14864,0.0,0.0,5.400000095367432,5.727750027179718,5.986666671435038,-0.37037001061669084,-5.722140984802496,-4.324888263626271,41.44998462629686,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-05-12,5.320000171661377,5.320000171661377,5.199999809265137,5.300000190734863,28017,0.0,0.0,5.386000108718872,5.712000036239624,5.980000007152557,-1.5967307138518632,-5.707281608061182,-4.481604859404406,38.79921068029513,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-05-15,5.300000190734863,5.300000190734863,5.0,5.239999771118164,31993,0.0,0.0,5.364000082015991,5.693250036239624,5.976166673501333,-2.311713441496131,-5.783163432623471,-4.734082108455542,36.893539190117785,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-05-16,5.260000228881836,5.300000190734863,5.119999885559082,5.260000228881836,24635,0.0,0.0,5.34800009727478,5.679000043869019,5.970416676998139,-1.645472453109844,-5.82848994607039,-4.881009967894583,37.986938140424066,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-05-17,5.179999828338623,5.300000190734863,5.079999923706055,5.239999771118164,34784,0.0,0.0,5.346000051498413,5.660500037670135,5.963666673501333,-1.9827960972529022,-5.556046004394533,-5.083561044386895,37.29112127107989,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-05-19,5.039999961853027,6.980000019073486,5.039999961853027,5.920000076293945,13839,0.0,0.0,5.400000047683716,5.6585000395774845,5.962916672229767,9.629630074415997,-4.5683483270430525,-5.105163284773005,62.46502788497162,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-05-22,5.880000114440918,5.880000114440918,5.360000133514404,5.519999980926514,52873,0.0,0.0,5.402000045776367,5.645250034332276,5.960583337148031,2.1843749379899915,-4.308932059280888,-5.290309437509407,49.80045465146727,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-05-23,5.460000038146973,5.880000114440918,5.400000095367432,5.579999923706055,15221,0.0,0.0,5.4220000267028805,5.633500027656555,5.958000004291534,2.9140519407052445,-3.7543267935627416,-5.4464581470500635,51.39241799588705,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-05-24,5.579999923706055,5.980000019073486,5.139999866485596,5.639999866485596,37310,0.0,0.0,5.4480000019073485,5.630500018596649,5.957500004768372,3.524226587941042,-3.241275483288022,-5.4888793270665985,52.99764901910533,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-05-25,5.639999866485596,5.639999866485596,5.079999923706055,5.460000038146973,31022,0.0,0.0,5.453999996185303,5.6175000190734865,5.952000006039937,0.11001177055127498,-2.9105477940906246,-5.619959452738724,47.88826476090007,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-05-26,5.460000038146973,5.579999923706055,5.21999979019165,5.360000133514404,35466,0.0,0.0,5.451999998092651,5.600250017642975,5.945250006516774,-1.6874516619668434,-2.647203590612536,-5.802951742914664,45.27671077336651,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-05-29,5.360000133514404,5.840000152587891,5.0,5.420000076293945,43078,0.0,0.0,5.46399998664856,5.588250017166137,5.940916673342387,-0.8052692251487793,-2.223415740811581,-5.936233001864974,47.139389754466926,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-05-30,5.679999828338623,5.679999828338623,5.239999771118164,5.420000076293945,30893,0.0,0.0,5.482000017166138,5.579000020027161,5.934833339850107,-1.1309730149224433,-1.7386628878440245,-5.995675016409702,47.139389754466926,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-05-31,5.360000133514404,5.5,5.199999809265137,5.380000114440918,15570,0.0,0.0,5.494000005722046,5.561250019073486,5.927583340803782,-2.0749889181360746,-1.2092607439117509,-6.1801462867432395,45.9306128097238,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-06-01,5.440000057220459,5.559999942779541,5.21999979019165,5.239999771118164,18553,0.0,0.0,5.494000005722046,5.540000009536743,5.9226666728655495,-4.623229602099351,-0.8303249771752943,-6.461053516348943,41.88253051793369,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-06-02,5.119999885559082,5.5,5.0,5.480000019073486,49701,0.0,0.0,5.45,5.529000008106232,5.91941667397817,0.5504590655685532,-1.4288299509930835,-6.59552600154361,50.015509265058235,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-06-05,6.059999942779541,7.5,6.059999942779541,7.159999847412109,302280,0.0,0.0,5.61399998664856,5.561000001430512,5.929666674137115,27.53829469968487,0.9530657292647826,-6.217325407422701,75.67586223413005,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-06-07,7.21999979019165,8.899999618530273,7.21999979019165,7.980000019073486,398139,0.0,0.0,5.853999996185303,5.615499997138977,5.947833339373271,36.31704858683923,4.247172988475438,-5.587468970159676,80.84481997494659,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-06-08,8.5,8.5,7.78000020980835,7.880000114440918,38126,0.0,0.0,6.078000020980835,5.6625,5.963583342234293,29.647911932209663,7.337748714893342,-5.0486984914256405,78.64982459050738,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-06-09,7.800000190734863,7.800000190734863,7.21999979019165,7.400000095367432,76721,0.0,0.0,6.272000026702881,5.702499997615814,5.976666676998138,17.984694895760825,9.986848387990735,-4.5872840865876725,68.96999015352695,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-06-12,7.400000095367432,7.400000095367432,6.880000114440918,7.159999847412109,51286,0.0,0.0,6.451999998092651,5.738999998569488,5.987166674931844,10.973339267339712,12.42376720161851,-4.144976912058004,64.68334290433056,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-06-13,7.159999847412109,7.880000114440918,7.019999980926514,7.539999961853027,13444,0.0,0.0,6.66399998664856,5.786000001430511,6.003333342075348,13.145257757496232,15.174559021793549,-3.620211110411284,68.06747681067728,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-06-14,7.900000095367432,8.100000381469727,7.300000190734863,7.659999847412109,67473,0.0,0.0,6.887999963760376,5.835000002384186,6.01941667397817,11.207896163087002,18.046271824266206,-3.0636967264820467,69.07523457412078,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-06-15,7.980000019073486,8.0,7.139999866485596,7.480000019073486,47115,0.0,0.0,7.097999954223633,5.876999998092652,6.034250009059906,5.3817986378338265,20.77590533481794,-2.60595783620428,65.72460187308025,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-06-16,7.480000019073486,7.980000019073486,7.360000133514404,7.860000133514404,21340,0.0,0.0,7.3599999904632565,5.93050000667572,6.049916676680247,6.793480213301965,24.10420676466415,-1.973856441111415,69.12907857529642,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-06-19,7.860000133514404,8.0,7.639999866485596,7.920000076293945,34609,0.0,0.0,7.603999996185303,5.988500010967255,6.06775000890096,4.155708577948052,26.976705055680796,-1.3060854158040658,69.64181648969091,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-06-20,7.920000076293945,7.920000076293945,7.539999961853027,7.539999961853027,24796,0.0,0.0,7.642000007629394,6.040500009059906,6.081833342711131,-1.334729726178163,26.51270583838195,-0.6796196364170567,62.555377330588655,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-06-21,7.539999961853027,7.880000114440918,7.239999771118164,7.480000019073486,78532,0.0,0.0,7.5920000076293945,6.085500013828278,6.096666677792867,-1.475236939454117,24.75556635244184,-0.18316015217403858,61.49141981803683,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-06-22,7.5,7.599999904632568,7.199999809265137,7.579999923706055,55800,0.0,0.0,7.561999988555908,6.132500016689301,6.110750011603037,0.23803140938094208,23.310231846331718,0.3559302057024928,62.6321710250457,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-06-26,7.579999923706055,7.579999923706055,7.0,7.159999847412109,41976,0.0,0.0,7.537999963760376,6.172000014781952,6.121250009536743,-5.014594297765142,22.1322091008887,0.8290791123731642,55.231745897966384,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-06-27,7.0,7.760000228881836,6.820000171661377,7.440000057220459,52099,0.0,0.0,7.565999984741211,6.217500019073486,6.132750010490417,-1.6653440097127052,21.688781045933545,1.3819250489274686,58.73249574637867,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-06-28,7.400000095367432,7.400000095367432,7.059999942779541,7.360000133514404,75057,0.0,0.0,7.548000001907349,6.265500020980835,6.142333344618479,-2.4907242759067025,20.46923592102621,2.0052099007336777,57.35255763180359,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-06-29,7.519999980926514,7.760000228881836,6.71999979019165,6.840000152587891,72735,0.0,0.0,7.466000032424927,6.300000023841858,6.147333347797394,-8.38467555743787,18.507936574133854,2.483461810301288,49.252183446067356,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-06-30,6.920000076293945,7.260000228881836,6.519999980926514,7.099999904632568,47803,0.0,0.0,7.428000020980835,6.342000019550324,6.153583347797394,-4.415725840358243,17.12393563675065,3.0619016775058636,52.83884972440031,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-07-03,7.099999904632568,7.480000019073486,6.860000133514404,7.320000171661377,35194,0.0,0.0,7.374000024795532,6.393500018119812,6.1588333487510685,-0.7323006909760997,15.335888072212192,3.81024548125386,55.69240779988602,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-07-04,7.0,7.5,6.900000095367432,7.21999979019165,139959,0.0,0.0,7.303999996185302,6.43950001001358,6.15916668176651,-1.1500575853987296,13.424955118058914,4.551481437853664,54.09032467118853,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-07-05,7.199999809265137,7.199999809265137,6.920000076293945,7.079999923706055,24819,0.0,0.0,7.257999992370605,6.479000008106231,6.158416680494944,-2.45246719277568,12.023460152642757,5.205612809971842,51.84188874332464,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-07-06,7.199999809265137,7.440000057220459,7.119999885559082,7.300000190734863,99106,0.0,0.0,7.240000009536743,6.52700001001358,6.161750014623006,0.8287317834127913,10.923854733097807,5.927699022579074,55.00698072372306,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-07-07,7.679999828338623,7.679999828338623,7.179999828338623,7.380000114440918,28491,0.0,0.0,7.2200000286102295,6.57700001001358,6.166083347797394,2.21606766200369,9.776494110045192,6.66414381769541,56.135936169662976,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-07-10,7.079999923706055,7.380000114440918,7.019999980926514,7.179999828338623,21768,0.0,0.0,7.222000026702881,6.62150000333786,6.170083347956339,-0.5815591000964433,9.068942430904066,7.316216490512066,52.58364864897663,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-07-11,7.199999809265137,7.699999809265137,7.039999961853027,7.639999866485596,148172,0.0,0.0,7.242000007629395,6.677999997138977,6.178333346048991,5.495717459775074,8.445642568614094,8.087401943268741,59.00862535179848,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-07-12,7.639999866485596,7.639999866485596,7.300000190734863,7.460000038146973,13366,0.0,0.0,7.251999998092652,6.73199999332428,6.185416678587596,2.868174849821112,7.724301920440057,8.836645017445989,55.821189743095125,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-07-13,7.260000228881836,7.599999904632568,7.260000228881836,7.559999942779541,27731,0.0,0.0,7.323999977111816,6.789999997615814,6.191833345095317,3.2222824468220495,7.864506328181246,9.660574165716488,57.20424272225366,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-07-14,7.320000171661377,7.539999961853027,7.199999809265137,7.5,47644,0.0,0.0,7.36399998664856,6.845999991893768,6.197666676839193,1.8468225637970868,7.566462100031361,10.460925842904883,56.07003765833088,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-07-17,7.5,7.679999828338623,7.159999847412109,7.579999923706055,34790,0.0,0.0,7.389999961853027,6.904499995708465,6.204583342870077,2.5710414456536155,7.031645541984606,11.28063907212544,57.28610040318611,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-07-18,7.579999923706055,7.679999828338623,7.320000171661377,7.599999904632568,50072,0.0,0.0,7.427999973297119,6.946499991416931,6.213333340485891,2.3155618195176486,6.931548009431047,11.799892437023278,57.60208386749323,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-07-19,7.679999828338623,7.679999828338623,7.320000171661377,7.420000076293945,12247,0.0,0.0,7.461999988555908,6.993999993801117,6.222583341598511,-0.5628506074293176,6.691449745061287,12.397048136673696,53.74830244503822,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-07-20,7.519999980926514,7.679999828338623,7.320000171661377,7.619999885559082,22335,0.0,0.0,7.49399995803833,7.044999992847442,6.232000009218852,1.6813441183116098,6.373313919755043,13.045570963189004,57.176553912058125,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-07-21,7.619999885559082,7.619999885559082,7.420000076293945,7.440000057220459,17967,0.0,0.0,7.499999952316284,7.089999997615815,6.239250008265177,-0.7999986063639257,5.7827920287495385,13.63545279037774,53.34425117523758,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-07-24,7.440000057220459,7.880000114440918,7.440000057220459,7.679999828338623,36651,0.0,0.0,7.549999952316284,7.145499992370605,6.24925000667572,1.721852673422281,5.66090491046913,14.341720762291022,57.44028869556902,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-07-25,7.5,7.860000133514404,7.420000076293945,7.559999942779541,24073,0.0,0.0,7.541999959945679,7.2004999876022335,6.260250008106231,0.23866325814713468,4.742725823643325,15.019367889117808,54.84748197487594,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-07-26,7.559999942779541,7.599999904632568,7.400000095367432,7.579999923706055,12155,0.0,0.0,7.553999948501587,7.254499983787537,6.2712500055631,0.34418818350171304,4.128471505732674,15.678692084547977,55.2103632036254,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-07-27,7.400000095367432,7.480000019073486,7.320000171661377,7.320000171661377,25609,0.0,0.0,7.5299999713897705,7.301999986171722,6.280750008424123,-2.7888419724606592,3.122432013829453,16.260000419979097,49.62662202714748,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-07-28,7.320000171661377,7.579999923706055,7.119999885559082,7.28000020980835,14193,0.0,0.0,7.507999992370605,7.349499988555908,6.290000009536743,-3.0367578954973595,2.1566093484114766,16.844196779217445,48.808771610080804,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-07-31,7.760000228881836,7.760000228881836,7.199999809265137,7.239999771118164,24068,0.0,0.0,7.473999977111816,7.399499988555908,6.299666674931844,-3.1308563916276224,1.006824632355301,17.458595357125986,47.957620534524835,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-08-01,7.239999771118164,7.400000095367432,7.199999809265137,7.199999809265137,16926,0.0,0.0,7.433999967575073,7.442499983310699,6.307166671752929,-3.1477019011377014,-0.11420914685504298,18.000686689356673,47.073593326097686,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-08-02,7.199999809265137,7.380000114440918,6.920000076293945,7.199999809265137,31390,0.0,0.0,7.411999940872192,7.443499982357025,6.316416668891907,-2.8602284578824344,-0.4231885747228564,17.843713810331067,47.073593326097686,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-08-03,7.440000057220459,7.440000057220459,7.019999980926514,7.079999923706055,14158,0.0,0.0,7.35799994468689,7.420999979972839,6.325916667779286,-3.778200911534055,-0.8489426688582148,17.31106130074871,44.236464624975916,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-08-04,7.099999904632568,7.320000171661377,7.0,7.28000020980835,42088,0.0,0.0,7.341999959945679,7.4059999823570255,6.335166668891906,-0.8444531527590473,-0.8641644958656621,16.90300144309258,49.67995178778617,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-08-07,7.28000020980835,7.860000133514404,7.0,7.860000133514404,82885,0.0,0.0,7.3599999904632565,7.4174999833107,6.3501666704813635,6.793480213301965,-0.7751937037656589,16.807957463397237,61.43661451987249,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-08-08,7.880000114440918,7.880000114440918,7.360000133514404,7.599999904632568,25542,0.0,0.0,7.36399998664856,7.428499984741211,6.363583338260651,3.20477890293173,-0.8682775556995285,16.734543886269464,55.20949420686587,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-08-09,7.860000133514404,7.900000095367432,7.519999980926514,7.699999809265137,22662,0.0,0.0,7.375999975204468,7.432499980926513,6.377333335081736,4.392622493897007,-0.7601749864384474,16.54557775803096,57.014156615023374,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-08-10,7.699999809265137,7.760000228881836,7.5,7.599999904632568,25679,0.0,0.0,7.403999948501587,7.430999982357025,6.391416668891907,2.647217146059642,-0.3633432097906372,16.265303411134873,54.643162296237,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-08-11,7.900000095367432,7.900000095367432,7.5,7.639999866485596,52887,0.0,0.0,7.439999914169311,7.4349999785423275,6.404750001430512,2.6881714331123736,0.06724863001228827,16.085717270489994,55.441385163961414,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-08-14,7.639999866485596,7.639999866485596,7.199999809265137,7.5,32950,0.0,0.0,7.465999937057495,7.425999975204467,6.4167500019073485,0.45539865026981724,0.5386474816400196,15.728366743244232,51.99252910571554,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-08-15,7.5,7.5,7.199999809265137,7.380000114440918,16179,0.0,0.0,7.483999967575073,7.412499976158142,6.4302500009536745,-1.3896292568778934,0.9645867338537115,15.275455465320784,49.16913527766958,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-08-16,7.380000114440918,7.400000095367432,7.079999923706055,7.380000114440918,16394,0.0,0.0,7.501999998092652,7.40849997997284,6.442916667461395,-1.6262314540489424,1.2620640935758602,14.986742221700952,49.16913527766958,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-08-17,7.400000095367432,7.400000095367432,7.079999923706055,7.21999979019165,24572,0.0,0.0,7.515999984741211,7.401999974250794,6.4540000001589455,-3.938267631060307,1.5401244378139303,14.688564829075016,45.3601087106461,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-08-18,6.800000190734863,7.320000171661377,6.800000190734863,7.199999809265137,29441,0.0,0.0,7.5079999446868895,7.39249997138977,6.465083332856496,-4.102292723639564,1.5623939633970056,14.345006719712455,44.891960459840284,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-08-21,7.059999942779541,7.199999809265137,7.0,7.159999847412109,10951,0.0,0.0,7.43799991607666,7.39249997138977,6.474916664759318,-3.737564826582955,0.6154879250995268,14.171353148443341,43.91574814248213,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-08-22,7.199999809265137,7.300000190734863,7.079999923706055,7.239999771118164,10154,0.0,0.0,7.40199990272522,7.387499964237213,6.485999997456869,-2.1885994830587836,0.19627666407040448,13.899166930832843,46.425045897346564,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-08-23,7.239999771118164,7.480000019073486,7.099999904632568,7.239999771118164,9117,0.0,0.0,7.355999898910523,7.384499955177307,6.497999993960063,-1.5769457502241,-0.38594429466822316,13.642658695617914,46.425045897346564,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-08-24,7.260000228881836,7.300000190734863,7.059999942779541,7.300000190734863,15502,0.0,0.0,7.325999927520752,7.395999956130981,6.5105833292007445,-0.35489676553529015,-0.9464579370664,13.5996512472091,48.43194749656344,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-08-25,7.460000038146973,7.5,7.239999771118164,7.400000095367432,18504,0.0,0.0,7.301999950408936,7.403499960899353,6.523916661739349,1.342100049631025,-1.3709733372928556,13.482442292962965,51.680687802446954,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-08-28,7.400000095367432,7.519999980926514,7.28000020980835,7.480000019073486,22618,0.0,0.0,7.299999952316284,7.407499957084656,6.537749993801117,2.4657543552461023,-1.4512319323816751,13.303506009073573,54.168257760993804,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-08-29,7.5,7.860000133514404,7.0,7.679999828338623,79085,0.0,0.0,7.329999923706055,7.41899995803833,6.55258332490921,4.774896429406892,-1.1996230601921698,13.222519885180164,59.74746493791302,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-08-30,7.78000020980835,7.840000152587891,7.519999980926514,7.800000190734863,24624,0.0,0.0,7.371999931335449,7.43699996471405,6.566749993960062,5.805755064920096,-0.8740087896598497,13.252369460607188,62.682769606266355,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-08-31,7.800000190734863,8.0,7.559999942779541,7.900000095367432,91683,0.0,0.0,7.439999961853028,7.4519999623298645,6.581666660308838,6.182797525174113,-0.16103060302599637,13.22360044864665,64.97490853940658,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-09-01,8.0,8.0,7.539999961853027,7.679999828338623,39825,0.0,0.0,7.487999963760376,7.459499955177307,6.595666658878327,2.5641007679950283,0.3820632583191864,13.096982321509346,56.720600706786726,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-09-04,7.679999828338623,7.679999828338623,7.0,7.639999866485596,119592,0.0,0.0,7.535999965667725,7.4709999561309814,6.609416659673055,1.3800411530211045,0.8700309184636242,13.035693478288682,55.34394249286007,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-09-05,7.599999904632568,7.599999904632568,7.239999771118164,7.380000114440918,26376,0.0,0.0,7.55,7.464499962329865,6.6234166622161865,-2.2516541133653223,1.1454221729736382,12.698631884533334,47.30671691330632,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-09-06,7.380000114440918,7.679999828338623,7.0,7.239999771118164,21266,0.0,0.0,7.55,7.458999955654145,6.634333328406016,-4.105963296448156,1.2200032831059937,12.43028630649563,43.6323266110807,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-09-07,7.340000152587891,7.340000152587891,7.0,7.179999828338623,25987,0.0,0.0,7.537999963760376,7.449499952793121,6.64424999554952,-4.749272182845197,1.187999349326423,12.119501189494338,42.122312177773836,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-09-08,7.139999866485596,7.579999923706055,6.940000057220459,7.079999923706055,36011,0.0,0.0,7.505999946594239,7.438999950885773,6.6546666622161865,-5.675459977607335,0.9006586389409525,11.78621452405524,39.65884798240036,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-09-11,7.199999809265137,7.300000190734863,7.0,7.099999904632568,36187,0.0,0.0,7.4679999351501465,7.426999950408936,6.663999994595845,-4.92769193509881,0.5520396528204243,11.449579178148914,40.409477988130135,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-09-12,7.579999923706055,7.579999923706055,6.880000114440918,7.199999809265137,23193,0.0,0.0,7.4199999332427975,7.41699994802475,6.6739999930063885,-2.9649612662666573,0.04044742131684254,11.132753308314998,44.15046800684397,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-09-13,7.199999809265137,7.679999828338623,6.840000152587891,7.320000171661377,80888,0.0,0.0,7.371999931335449,7.414499950408936,6.684583326180776,-0.7053684232014447,-0.5732014209689529,10.919403478289746,48.34148063150612,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-09-14,7.28000020980835,7.679999828338623,6.71999979019165,7.159999847412109,37876,0.0,0.0,7.297999906539917,7.402999949455261,6.693833323319753,-1.8909298560574412,-1.4183445040151712,10.594327523288301,43.63929133240484,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-09-15,7.360000133514404,7.360000133514404,7.099999904632568,7.21999979019165,25700,0.0,0.0,7.2519999027252195,7.397499942779541,6.705999986330668,-0.4412591417926505,-1.9668812596117649,10.311660570510115,45.76957683011075,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-09-18,7.21999979019165,7.239999771118164,7.099999904632568,7.199999809265137,17593,0.0,0.0,7.207999897003174,7.385499942302704,6.7161666512489315,-0.11098901016027254,-2.4033585632144416,9.966001825301692,45.15687570086575,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-09-19,7.460000038146973,7.559999942779541,7.119999885559082,7.559999942779541,40363,0.0,0.0,7.225999879837036,7.385499942302704,6.7287499825159705,4.622198567626292,-2.1596379894620603,9.760356106159938,56.45627024592806,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-09-20,7.559999942779541,7.900000095367432,7.260000228881836,7.659999847412109,39302,0.0,0.0,7.267999887466431,7.387499940395355,6.7434166471163435,5.393505311161018,-1.6175980222414659,9.55129019878133,58.98420426629765,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-09-21,7.900000095367432,7.900000095367432,7.519999980926514,7.860000133514404,23228,0.0,0.0,7.335999917984009,7.4009999394416806,6.760666648546855,7.1428601606963324,-0.8782599917515347,9.471451917133935,63.5428751450838,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-09-22,7.860000133514404,7.860000133514404,7.559999942779541,7.800000190734863,25109,0.0,0.0,7.40799994468689,7.413999938964844,6.774916648864746,5.291580034758518,-0.08092789759035268,9.43307974434176,61.340264939216695,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-09-25,7.800000190734863,7.860000133514404,7.420000076293945,7.71999979019165,40026,0.0,0.0,7.469999933242798,7.425999939441681,6.788499979178111,3.346718329090063,0.5925127142463378,9.39088108151917,58.431913384030224,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-09-26,7.659999847412109,7.800000190734863,7.5,7.760000228881836,24112,0.0,0.0,7.525999975204468,7.439999949932099,6.80383331378301,3.1092247468551264,1.1559143259557987,9.350120833506608,59.466745750380035,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-09-27,7.760000228881836,7.960000038146973,7.639999866485596,7.840000152587891,22481,0.0,0.0,7.5779999732971195,7.455999958515167,6.820166647434235,3.4573789946422657,1.6362663017805095,9.322841272802838,61.52949915034162,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-09-28,7.840000152587891,8.0,7.599999904632568,7.860000133514404,43240,0.0,0.0,7.648000001907349,7.475499963760376,6.837333313624064,2.771968247308899,2.3075384788069866,9.333560627572473,62.049469266663216,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-09-29,7.860000133514404,7.940000057220459,7.539999961853027,7.659999847412109,17418,0.0,0.0,7.692000007629394,7.48499995470047,6.851166645685832,-0.4160187231610126,2.765531785994617,9.251465360483703,54.165276606274595,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-10-02,7.639999866485596,8.15999984741211,7.519999980926514,7.739999771118164,40879,0.0,0.0,7.746000003814697,7.481999945640564,6.8673333088556925,-0.07746233789799158,3.5284691271343123,8.950586918392839,56.543836951372164,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-10-03,7.739999771118164,7.940000057220459,7.260000228881836,7.5,41963,0.0,0.0,7.740000009536743,7.47949994802475,6.88233331044515,-3.1007753131916043,3.482853978504115,8.676804953245943,48.42497907211881,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-10-04,7.480000019073486,7.900000095367432,7.380000114440918,7.400000095367432,44928,0.0,0.0,7.714000034332275,7.471999955177307,6.896833312511444,-4.07052032107002,3.238759108761603,8.339575811154688,45.49384458732287,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-10-05,7.400000095367432,7.71999979019165,7.260000228881836,7.5,8945,0.0,0.0,7.678000020980835,7.469499957561493,6.911833314100901,-2.318312327356519,2.791352360987348,8.068288370364638,48.82942405459156,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-10-06,10.800000190734863,12.199999809265137,9.420000076293945,9.819999694824219,1322677,0.0,0.0,7.87999997138977,7.523999953269959,6.945333309968313,24.619285919772626,4.731526054370752,8.331733229722936,79.76623289453894,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-10-09,9.819999694824219,11.149999618530273,9.600000381469727,9.699999809265137,608256,0.0,0.0,8.07799997329712,7.578999948501587,6.978499976793925,20.07922556734029,6.583982427578558,8.605000697922833,77.16746768054008,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-10-10,10.050000190734863,10.149999618530273,9.399999618530273,9.84000015258789,248160,0.0,0.0,8.285999965667724,7.640499949455261,7.013833312193553,18.754528039573053,8.448400241904123,8.934723843126529,78.06533451621205,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-10-11,9.84000015258789,10.350000381469727,9.5,10.199999809265137,272519,0.0,0.0,8.521999931335449,7.710999941825866,7.053333310286204,19.69021229112748,10.517442557748847,9.324196129800875,80.21938245607247,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-10-12,10.199999809265137,10.449999809265137,9.699999809265137,10.25,255621,0.0,0.0,8.760999917984009,7.786749947071075,7.091416645050049,16.99577783306982,12.511638071534453,9.80528062057083,80.50572488050175,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-10-13,10.100000381469727,10.350000381469727,9.800000190734863,10.149999618530273,121095,0.0,0.0,9.009999895095826,7.860499942302704,7.1284999767939246,12.65260529087191,14.623751176523509,10.268639515911172,78.07154154164272,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-10-16,10.149999618530273,10.199999809265137,9.520000457763672,9.680000305175781,146758,0.0,0.0,9.203999948501586,7.923499953746796,7.162666646639506,5.171668397843571,16.160787558902914,10.622207407408082,67.70927137294566,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-10-17,10.0,10.0,9.180000305175781,9.739999771118164,105460,0.0,0.0,9.427999925613403,7.985999953746796,7.196999979019165,3.3092898596354434,18.05659880063063,10.962900889644835,68.28792890121761,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-10-18,9.800000190734863,9.800000190734863,9.100000381469727,9.199999809265137,76742,0.0,0.0,9.607999897003173,8.03499995470047,7.228333310286204,-4.246462240963344,19.57685066796421,11.159787599533466,58.18225380877607,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-10-19,9.399999618530273,9.539999961853027,9.020000457763672,9.479999542236328,103870,0.0,0.0,9.805999851226806,8.089499938488007,7.2618333061536156,-3.3244984084890947,21.218863042103276,11.3974887255128,61.37414492467847,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-10-20,9.479999542236328,9.579999923706055,9.140000343322754,9.460000038146973,19543,0.0,0.0,9.769999885559082,8.140999937057495,7.29549997250239,-3.1729769809958412,20.009826324730042,11.589335449823803,61.015902694771256,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-10-23,9.4399995803833,9.460000038146973,9.260000228881836,9.460000038146973,7091,0.0,0.0,9.745999908447265,8.190499937534332,7.330499970912934,-2.934535942816956,18.991514349259624,11.731805061507893,61.01590269477124,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-10-24,9.460000038146973,9.479999542236328,9.199999809265137,9.380000114440918,8572,0.0,0.0,9.699999904632568,8.23299994468689,7.363833304246267,-3.298966941626702,17.818534796570678,11.80318190988148,59.40722044208716,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-10-25,9.380000114440918,9.579999923706055,8.5600004196167,9.380000114440918,46379,0.0,0.0,9.617999935150147,8.272499942779541,7.396166638533274,-2.4745250812430313,16.2647325678738,11.848479720300782,59.40722044208716,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-10-26,9.380000114440918,9.479999542236328,9.0,9.140000343322754,73004,0.0,0.0,9.506999969482422,8.303499948978423,7.427499973773957,-3.860309533372683,14.493888455458649,11.794008459071941,54.41560295981644,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-10-27,9.140000343322754,9.380000114440918,8.979999542236328,9.279999732971191,63205,0.0,0.0,9.419999980926514,8.343499946594239,7.4599999705950415,-1.4862022106029,12.902259737793791,11.843163263829421,56.70109131410946,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-10-30,9.279999732971191,9.34000015258789,8.920000076293945,9.180000305175781,76151,0.0,0.0,9.369999980926513,8.381999957561494,7.491499972343445,-2.0277446759604447,11.78716330669668,11.886804892284982,54.595492430870024,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-10-31,9.34000015258789,9.460000038146973,9.180000305175781,9.399999618530273,34474,0.0,0.0,9.335999965667725,8.432499945163727,7.524999968210856,0.6855147075610714,10.714497792818607,12.059800409123966,58.267216760364434,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-11-01,9.399999618530273,9.399999618530273,9.0600004196167,9.279999732971191,22330,0.0,0.0,9.34399995803833,8.483499944210052,7.558166631062826,-0.6849339186060363,10.143219419899498,12.242827636853868,55.624902027626696,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-11-02,9.119999885559082,9.300000190734863,8.920000076293945,9.260000228881836,29806,0.0,0.0,9.32200002670288,8.535499954223633,7.591666634877523,-0.6650911568702684,9.214458165277861,12.432491635103746,55.175813361244096,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-11-03,9.260000228881836,9.260000228881836,8.9399995803833,9.100000381469727,27321,0.0,0.0,9.286000061035157,8.585999965667725,7.623666636149088,-2.0030118279440985,8.15280803827716,12.622972323521427,51.58748470104454,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-11-06,9.100000381469727,9.100000381469727,8.9399995803833,9.100000381469727,16383,0.0,0.0,9.250000095367431,8.635999977588654,7.655833307902018,-1.6216185119049602,7.109774425337817,12.802873707751058,51.587484701044545,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-11-07,9.0,9.399999618530273,8.720000267028809,9.399999618530273,81610,0.0,0.0,9.252000045776366,8.690999972820283,7.684833304087321,1.5996495030441586,6.454954259699944,13.092888666795327,57.585744433200844,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-11-08,9.300000190734863,10.5,9.100000381469727,10.100000381469727,66922,0.0,0.0,9.324000072479247,8.760499978065491,7.722999974091848,8.322611571839479,6.432282356311236,13.433898840529823,67.65571536254265,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-11-09,9.960000038146973,10.100000381469727,9.699999809265137,9.720000267028809,48415,0.0,0.0,9.382000064849853,8.824499988555909,7.757499976952871,3.602645489689247,6.317639265872753,13.754431386052715,59.40970858485257,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-11-10,10.0,10.0,9.579999923706055,10.0,55445,0.0,0.0,9.454000091552734,8.893999993801117,7.793833311398824,5.775332167969024,6.296380685202635,14.115861071768759,62.98923695677847,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-11-13,10.0,10.0,9.65999984741211,9.9399995803833,51962,0.0,0.0,9.530000019073487,8.96249998807907,7.83116664091746,4.302198955815681,6.3319389874392495,14.446549269561565,61.732912651900605,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-11-14,10.0,10.149999618530273,9.699999809265137,10.100000381469727,19773,0.0,0.0,9.600000095367431,9.025999999046325,7.870666642983754,5.2083362618254085,6.359407227805825,14.678977124415304,63.8060313694467,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-11-15,10.100000381469727,10.199999809265137,9.65999984741211,10.100000381469727,41312,0.0,0.0,9.682000160217285,9.087000012397766,7.909666645526886,4.31729202990491,6.547817178471839,14.884740655115875,63.8060313694467,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-11-16,10.0,10.050000190734863,9.779999732971191,9.899999618530273,19313,0.0,0.0,9.74600009918213,9.137999999523164,7.9469999750455225,1.5801304923141468,6.653535781250739,14.98678782203996,59.159765366053016,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-11-17,9.899999618530273,9.899999618530273,9.220000267028809,9.420000076293945,74357,0.0,0.0,9.77800006866455,9.17849999666214,7.980666641394297,-3.661280321707947,6.5315691258966595,15.009189195485181,49.789099311741126,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-11-20,9.420000076293945,9.779999732971191,9.319999694824219,9.319999694824219,15666,0.0,0.0,9.8,9.218499994277954,8.014666640758515,-4.897962297712061,6.307967739686411,15.020379605027554,48.08043053692439,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-11-21,9.399999618530273,9.399999618530273,9.119999885559082,9.380000114440918,27292,0.0,0.0,9.798000049591064,9.258999991416932,8.047166641553243,-4.266176087308672,5.821363631858554,15.059130795255705,49.206763549837824,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-11-22,9.380000114440918,9.399999618530273,9.100000381469727,9.300000190734863,67069,0.0,0.0,9.718000030517578,9.295499992370605,8.064999977747599,-4.301294900906189,4.545210461984241,15.257284786337486,47.72028472890375,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-11-23,9.380000114440918,9.380000114440918,9.079999923706055,9.380000114440918,19639,0.0,0.0,9.684000015258789,9.333499991893769,8.076666645208995,-3.1391976491002427,3.7552903377021796,15.561287866576933,49.367491254980386,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-11-24,9.380000114440918,9.5,9.220000267028809,9.380000114440918,40724,0.0,0.0,9.622000026702882,9.37649999856949,8.089166645208994,-2.5150687132650984,2.6182480474681027,15.914288947464685,49.36749125498039,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-11-27,9.380000114440918,9.680000305175781,9.239999771118164,9.579999923706055,63203,0.0,0.0,9.586000061035156,9.422500002384187,8.10733331044515,-0.06259271115061181,1.7352089000753383,16.221939342800074,53.60575811613032,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-11-28,9.579999923706055,9.699999809265137,9.359999656677246,9.5600004196167,8759,0.0,0.0,9.532000064849854,9.474000012874603,8.127333315213521,0.29375109710814673,0.6122023632724506,16.569600943279415,53.126855409467716,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-11-29,9.460000038146973,9.699999809265137,9.34000015258789,9.600000381469727,16889,0.0,0.0,9.482000064849853,9.52900002002716,8.144499985376994,1.2444665240755013,-0.4932307175834545,16.9992023713667,54.011782437954516,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-11-30,9.600000381469727,9.600000381469727,9.15999984741211,9.399999618530273,12539,0.0,0.0,9.432000064849854,9.576500010490417,8.158999983469645,-0.33927529791731237,-1.508901430400176,17.37345299537523,49.02773717450545,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-12-01,9.0600004196167,9.399999618530273,9.0600004196167,9.279999732971191,32903,0.0,0.0,9.418000030517579,9.563000011444093,8.17399998108546,-1.4652824070845054,-1.516260386416307,16.99290474153122,46.26895733339432,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-12-04,9.279999732971191,9.479999542236328,9.0,9.260000228881836,17838,0.0,0.0,9.41200008392334,9.552000021934509,8.185666648546855,-1.6149580714638494,-1.4656609892136012,16.691778837954633,45.80633792835566,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-12-05,9.0,9.359999656677246,8.720000267028809,9.100000381469727,46883,0.0,0.0,9.384000110626221,9.533500027656554,8.19549998442332,-3.026425040584774,-1.5681535280498853,16.326033137408196,42.17340157742184,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-12-06,9.100000381469727,9.460000038146973,8.920000076293945,9.420000076293945,33807,0.0,0.0,9.396000099182128,9.514000034332275,8.21116665204366,0.25542759534353543,-1.2402767997091824,15.866605045269116,50.61030768642982,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-12-07,9.420000076293945,9.420000076293945,8.84000015258789,9.020000457763672,33658,0.0,0.0,9.360000133514404,9.483250045776368,8.223999989032745,-3.6324751164621247,-1.299658995249799,15.311892733741697,42.30202245862578,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-12-08,9.0,9.180000305175781,8.9399995803833,9.15999984741211,34746,0.0,0.0,9.338000106811524,9.458500051498413,8.237166655063628,-1.9061925183484845,-1.27398576973946,14.827105576211638,45.66412047103104,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-12-11,9.15999984741211,9.300000190734863,9.0,9.0,54640,0.0,0.0,9.280000114440918,9.441500043869018,8.252499989668529,-3.0172425753012737,-1.7105325284934179,14.407755900503153,42.608337684339794,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-12-12,9.100000381469727,9.380000114440918,9.0,9.279999732971191,22679,0.0,0.0,9.252000045776366,9.430000042915344,8.267833320299784,0.30263388517390977,-1.8875927500414686,14.056484662821193,49.035744636249625,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-12-13,9.279999732971191,9.4399995803833,9.100000381469727,9.279999732971191,19915,0.0,0.0,9.219999980926513,9.432000041007996,8.283833316961925,0.6507565311149719,-2.247668142066995,13.860331082411955,49.03574463624963,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-12-14,9.319999694824219,9.4399995803833,9.140000343322754,9.279999732971191,16980,0.0,0.0,9.207999992370606,9.427000045776367,8.304166646798452,0.7819259411407627,-2.3231150137087444,13.521325459079117,49.03574463624964,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-12-15,9.15999984741211,9.34000015258789,9.100000381469727,9.279999732971191,15093,0.0,0.0,9.207999992370606,9.422500038146973,8.322333312034607,0.7819259411407627,-2.276466382679372,13.219450421691924,49.03574463624964,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-12-18,9.15999984741211,9.239999771118164,9.100000381469727,9.220000267028809,15442,0.0,0.0,9.203999996185303,9.416500043869018,8.33816664616267,0.17384040471683337,-2.256677605200794,12.932499954322829,47.50242986110325,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-12-19,9.199999809265137,9.220000267028809,8.920000076293945,9.140000343322754,16716,0.0,0.0,9.207999992370606,9.410500049591064,8.354166650772095,-0.7384844602975039,-2.151852251775483,12.6443898353565,45.461225191229765,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-12-20,8.920000076293945,9.239999771118164,8.920000076293945,9.119999885559082,17376,0.0,0.0,9.17799997329712,9.404000043869019,8.371166650454203,-0.6319469155239175,-2.403233406184863,12.337986287237229,44.9412875201784,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-12-21,9.0,9.199999809265137,9.0,9.199999809265137,32271,0.0,0.0,9.195999908447266,9.405500030517578,8.386999980608623,0.043496094581255404,-2.2274214171554556,12.143794590006006,47.526433386671954,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-12-22,9.199999809265137,9.380000114440918,9.039999961853027,9.260000228881836,55389,0.0,0.0,9.205999946594238,9.405000042915344,8.402666648228964,0.586577043242059,-2.1158968145992687,11.928753533232719,49.44370498721219,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-12-27,9.239999771118164,9.380000114440918,8.920000076293945,9.039999961853027,74254,0.0,0.0,9.209999942779541,9.401500034332276,8.418166649341583,-1.8458195655016336,-2.0369099702538658,11.681087176714469,43.20956496184061,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-12-28,9.020000457763672,9.260000228881836,8.640000343322754,9.180000305175781,78474,0.0,0.0,9.2,9.396000051498413,8.430999986330669,-0.21738798721976132,-2.085994576672627,11.445855375783617,47.72644119324006,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2023-12-29,9.100000381469727,9.300000190734863,8.960000038146973,9.239999771118164,87453,0.0,0.0,9.196000003814698,9.395000052452087,8.445833317438762,0.47846636891272726,-2.11814845690661,11.238284007494054,49.57737716164279,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-01-02,9.279999732971191,9.479999542236328,8.579999923706055,8.9399995803833,110645,0.0,0.0,9.161999988555909,9.387000036239623,8.457333314418793,-2.423056193515661,-2.396932425855706,10.992433279599535,41.638436283366424,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-01-03,8.920000076293945,8.920000076293945,8.579999923706055,8.779999732971191,65918,0.0,0.0,9.111999988555908,9.37900002002716,8.467999978860218,-3.643549780527743,-2.8467857010461817,10.758148836102865,38.131368694215325,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-01-04,9.0,9.279999732971191,8.859999656677246,8.979999542236328,84200,0.0,0.0,9.08799991607666,9.375999999046325,8.479666642347972,-1.188384406224291,-3.07167324017661,10.570384361833394,44.43180611250403,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-01-05,8.920000076293945,9.239999771118164,8.920000076293945,8.920000076293945,14728,0.0,0.0,9.06599988937378,9.364000010490418,8.490666643778484,-1.6104104882127794,-3.1824019733318156,10.285804440948901,43.01653984945167,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-01-08,9.279999732971191,9.319999694824219,9.0,9.319999694824219,52047,0.0,0.0,9.085999870300293,9.34449999332428,8.506499973932902,2.575388816467061,-2.766334455654769,9.851290448002397,53.62246831252192,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-01-09,9.319999694824219,9.319999694824219,8.84000015258789,8.84000015258789,25206,0.0,0.0,9.049999904632568,9.322499990463257,8.51666664282481,-2.3204392735648662,-2.923036590071887,9.461839724786605,43.22551715266212,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-01-10,8.84000015258789,9.279999732971191,8.699999809265137,9.0,44336,0.0,0.0,9.023999881744384,9.297499990463256,8.529666642347971,-0.2659561398370138,-2.9416521537984432,9.001915084267855,46.91999913217786,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-01-11,9.0,9.180000305175781,8.739999771118164,9.0,88013,0.0,0.0,9.019999885559082,9.274000000953674,8.540666643778483,-0.22172822408902662,-2.7388410110898382,8.586371389514346,46.91999913217786,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-01-12,9.0,9.180000305175781,8.9399995803833,9.079999923706055,14567,0.0,0.0,9.009999847412109,9.248499989509583,8.553333310286204,0.7769153993276858,-2.5787981009677265,8.12743586628822,48.85011935604017,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-01-15,9.0,9.0600004196167,8.84000015258789,9.039999961853027,10686,0.0,0.0,8.989999866485595,9.221999979019165,8.565499977270763,0.5561745952169654,-2.515724496436666,7.664467964397605,47.91201201031262,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-01-16,9.0600004196167,9.0600004196167,8.800000190734863,8.979999542236328,24406,0.0,0.0,8.993999862670899,9.198999977111816,8.579333305358887,-0.1556628935772862,-2.2285043477658597,7.222783515892413,46.47041828607054,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-01-17,8.979999542236328,9.0,8.859999656677246,8.979999542236328,3706,0.0,0.0,9.013999843597412,9.187999963760376,8.593499966462453,-0.37719438596656446,-1.8937758037577357,6.918019428848051,46.47041828607053,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-01-18,9.0,9.039999961853027,8.699999809265137,9.039999961853027,38082,0.0,0.0,9.019999885559082,9.180999970436096,8.60849996805191,0.2217303386662438,-1.7536225399787904,6.650403723167357,48.27536857587297,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-01-19,8.899999618530273,9.300000190734863,8.899999618530273,9.199999809265137,93291,0.0,0.0,9.047999858856201,9.176499962806702,8.625166634718576,1.679928744253435,-1.4003171630940405,6.392146974515979,52.84181571992699,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-01-22,9.15999984741211,9.15999984741211,8.680000305175781,8.979999542236328,62221,0.0,0.0,9.013999843597412,9.168499946594238,8.63999996582667,-0.37719438596656446,-1.6851186551428945,6.116897949744401,46.732552269308286,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-01-23,8.979999542236328,9.0,8.619999885559082,8.819999694824219,61034,0.0,0.0,9.011999797821044,9.154499936103822,8.654499963919323,-2.1304938671131346,-1.556613023948807,5.777340970235169,42.852248053643784,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-01-24,8.600000381469727,8.979999542236328,8.4399995803833,8.600000381469727,31455,0.0,0.0,8.971999835968017,9.13499994277954,8.665499965349833,-4.146226719788545,-1.784347102709743,5.418036804651393,38.160383694870596,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-01-25,8.600000381469727,8.859999656677246,8.140000343322754,8.600000381469727,103360,0.0,0.0,8.93199987411499,9.110499954223632,8.671666634082793,-3.716967054683915,-1.9592786455796005,5.0605418618846,38.160383694870596,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-01-26,8.0600004196167,8.5,8.0600004196167,8.4399995803833,106215,0.0,0.0,8.867999839782716,9.082499933242797,8.678666631380716,-4.826344915787703,-2.361685604587689,4.653172186633855,34.9341745194056,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-01-29,8.199999809265137,8.9399995803833,8.020000457763672,8.399999618530273,113316,0.0,0.0,8.80399980545044,9.052499914169312,8.684499963124592,-4.588825486684532,-2.7450992662249063,4.237433964042727,34.156714644392494,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-01-30,8.399999618530273,8.920000076293945,8.020000457763672,8.199999809265137,27214,0.0,0.0,8.72599983215332,9.022499918937683,8.689499962329865,-6.027962789432947,-3.2862298636548277,3.83221080673706,30.501571407324846,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-01-31,7.980000019073486,8.15999984741211,7.860000133514404,8.119999885559082,29856,0.0,0.0,8.639999866485596,8.993499922752381,8.69349996248881,-6.018518390765077,-3.930617215801341,3.4508536441942574,29.1574972610628,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-02-01,8.119999885559082,8.279999732971191,7.539999961853027,8.140000343322754,81831,0.0,0.0,8.549999904632568,8.965499925613404,8.698833298683166,-4.795316560034901,-4.634432261761561,3.065544743461245,29.988127528602632,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-02-02,8.140000343322754,8.979999542236328,7.760000228881836,8.5,54063,0.0,0.0,8.479999923706055,8.95049991607666,8.708166631062825,0.2358499584184457,-5.256689534463939,2.7828278359925975,42.953614264149,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-02-05,8.239999771118164,8.979999542236328,8.079999923706055,8.5,36949,0.0,0.0,8.431999969482423,8.927499914169312,8.717499963442485,0.8064519777477113,-5.550265465703952,2.408946964238348,42.953614264149,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-02-06,8.899999618530273,8.899999618530273,8.039999961853027,8.300000190734863,17877,0.0,0.0,8.380000019073487,8.909499907493592,8.726499966780345,-0.9546518873095227,-5.943093259081285,2.0970600058429225,38.37473320056992,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-02-07,8.199999809265137,8.199999809265137,7.860000133514404,8.15999984741211,42434,0.0,0.0,8.335999965667725,8.884499907493591,8.734499967098236,-2.1113258035086546,-6.173672660666436,1.7173271619484403,35.52029638784428,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-02-08,8.140000343322754,8.800000190734863,7.900000095367432,8.0,19020,0.0,0.0,8.275999927520752,8.859499907493591,8.741499968369801,-3.334943571023373,-6.586150302674527,1.3498820517160666,32.54120487080951,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-02-09,8.0,8.479999542236328,7.519999980926514,8.100000381469727,45971,0.0,0.0,8.242000007629395,8.829999923706055,8.748666640122732,-1.7228782580468713,-6.659115754894246,0.9296649069964098,36.14585509067961,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-02-12,8.100000381469727,8.180000305175781,7.699999809265137,8.020000457763672,23799,0.0,0.0,8.204000091552734,8.798499941825867,8.755166645844778,-2.2428038973148934,-6.756831894116737,0.49494541604933495,34.55507905714603,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-02-13,8.020000457763672,8.380000114440918,7.760000228881836,8.140000343322754,8318,0.0,0.0,8.198000144958495,8.769999957084655,8.762166647116343,-0.7074871994410671,-6.522232781359164,0.08939923518676827,38.89893354867675,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-02-14,8.199999809265137,8.199999809265137,7.920000076293945,8.180000305175781,2095,0.0,0.0,8.204000186920165,8.74249997138977,8.768666648864746,-0.2925387761771098,-6.1595628965612885,-0.2984111327617103,40.32088613734301,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-02-15,7.980000019073486,8.0,7.800000190734863,7.940000057220459,25484,0.0,0.0,8.184000158309937,8.710499966144562,8.77249998251597,-2.981428352511981,-6.044426954606423,-0.7067542490165588,35.05023726666806,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-02-16,7.940000057220459,8.279999732971191,7.5,8.0,78868,0.0,0.0,8.134000158309936,8.681999957561493,8.77516665061315,-1.647407864542978,-6.3119074168421525,-1.0617085322835114,37.258313356687474,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-02-19,8.0,8.800000190734863,7.980000019073486,8.180000305175781,20166,0.0,0.0,8.102000188827514,8.65849996805191,8.77833331823349,0.9627266666301466,-6.427207729719535,-1.365103668741691,43.46759058275174,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-02-20,8.079999923706055,8.180000305175781,7.78000020980835,8.0,30902,0.0,0.0,8.072000169754029,8.628499972820283,8.779166650772094,-0.8919743339923973,-6.449554439580746,-1.716184279729566,39.28107328588164,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-02-21,7.980000019073486,9.5,7.980000019073486,8.300000190734863,125625,0.0,0.0,8.086000204086304,8.604499971866607,8.78433332045873,2.646549359971739,-6.02591399239465,-2.047205428479022,48.230483297149796,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-02-22,8.479999542236328,8.859999656677246,8.279999732971191,8.579999923706055,30153,0.0,0.0,8.14400019645691,8.592999970912933,8.7921666542689,5.353631099356176,-5.225180681669676,-2.265274205866708,54.91035210210316,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-02-23,8.800000190734863,8.800000190734863,8.5,8.65999984741211,24752,0.0,0.0,8.200000143051147,8.579999959468841,8.802833318710327,5.609752394343258,-4.428902310172256,-2.5313822399414976,56.63213543419475,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-02-26,8.699999809265137,9.180000305175781,8.65999984741211,9.020000457763672,78743,0.0,0.0,8.300000143051147,8.574499976634979,8.817666657765706,8.67470243738872,-3.2013509164595964,-2.75772140826588,63.404333667639904,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-02-27,9.020000457763672,9.100000381469727,8.760000228881836,9.100000381469727,36698,0.0,0.0,8.396000146865845,8.57849999666214,8.833666662375132,8.384947859567143,-2.1274098020318877,-2.8885702332397503,64.72267623246364,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-02-28,9.279999732971191,9.479999542236328,9.0,9.300000190734863,74632,0.0,0.0,8.508000135421753,8.591500008106232,8.852166664600372,9.308886256545057,-0.9718893395297156,-2.9446650336639055,67.84168497668988,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-02-29,9.34000015258789,9.5,9.0,9.220000267028809,28008,0.0,0.0,8.636000156402588,8.597500026226044,8.869833334287007,6.762391153886822,0.4478061071137234,-3.070331739021953,65.35266192995098,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-03-01,9.199999809265137,9.199999809265137,8.9399995803833,9.0,24254,0.0,0.0,8.736000156402588,8.599500024318695,8.884833335876465,3.0219761775522382,1.5873031187613316,-3.211464985005507,58.947687729455815,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-03-04,9.0,9.260000228881836,8.819999694824219,9.0,35848,0.0,0.0,8.81800012588501,8.59150003194809,8.898833334445953,2.063958624594863,2.636327685441003,-3.453635897508331,58.947687729455815,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-03-05,8.779999732971191,8.979999542236328,8.760000228881836,8.979999542236328,4388,0.0,0.0,8.916000080108642,8.595000016689301,8.913999998569489,0.7178046383205777,3.7347302245030862,-3.5786401383372275,58.344791882203445,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-03-06,8.979999542236328,8.979999542236328,8.779999732971191,8.960000038146973,56851,0.0,0.0,8.982000064849853,8.594000017642974,8.928500000635783,-0.24493460859541769,4.514778291951793,-3.746429780690922,57.70919101787151,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-03-07,8.899999618530273,9.0,8.699999809265137,8.800000190734863,12481,0.0,0.0,9.004000091552735,8.589000022411346,8.941833337148031,-2.265658582225667,4.831762347869667,-3.9458721878752905,52.757520019148394,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-03-08,9.15999984741211,9.15999984741211,8.520000457763672,8.899999618530273,23558,0.0,0.0,9.02800006866455,8.584500014781952,8.95300000111262,-1.4178162290733218,5.1662886961258065,-4.115938638276264,55.33691664037623,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-03-11,8.899999618530273,9.180000305175781,8.640000343322754,8.739999771118164,26242,0.0,0.0,9.0,8.577000010013581,8.962000000476838,-2.8888914320203996,4.931794211176049,-4.295915983516762,50.57854350666683,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-03-12,8.520000457763672,9.34000015258789,8.300000190734863,9.34000015258789,53920,0.0,0.0,9.023999977111817,8.58600002527237,8.974333333969117,3.501775003075866,5.101327166902184,-4.327154945614191,63.31717889775096,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-03-13,9.319999694824219,9.319999694824219,8.600000381469727,8.899999618530273,21520,0.0,0.0,8.983999919891357,8.584000027179718,8.983499995867412,-0.9349989103973533,4.659830981420202,-4.4470414523456565,52.608218289797875,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-03-14,8.800000190734863,9.199999809265137,8.520000457763672,8.699999809265137,55344,0.0,0.0,8.93199987411499,8.57550002336502,8.991666662693024,-2.5974033600491975,4.157190248716006,-4.628359290215965,48.58572341670234,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-03-15,8.960000038146973,8.960000038146973,8.5,8.5,10509,0.0,0.0,8.88199987411499,8.558000028133392,8.997833327452343,-4.3008317893390355,3.7859294802113563,-4.888213454421534,44.88939665004947,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-03-18,8.5,8.84000015258789,8.5,8.819999694824219,15189,0.0,0.0,8.863999843597412,8.554000031948089,9.00599999030431,-0.4963915788533691,3.624033323492095,-5.018875847688611,51.27651149376713,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-03-19,8.600000381469727,8.979999542236328,8.420000076293945,8.5,14716,0.0,0.0,8.81599988937378,8.546000039577484,9.011333322525024,-3.58439080466261,3.1593710337689713,-5.163867169183255,45.58676383430633,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-03-20,8.5,8.859999656677246,8.420000076293945,8.600000381469727,24016,0.0,0.0,8.779999923706054,8.546000039577484,9.019166660308837,-2.0501086993215973,2.738121729989358,-5.246234364574333,47.545578784777504,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-03-21,8.579999923706055,9.5,8.180000305175781,8.979999542236328,43176,0.0,0.0,8.797999858856201,8.55550001859665,9.029499991734822,2.06864840077172,2.8344321165617656,-5.249459810311192,54.280817252284464,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-03-22,8.579999923706055,9.079999923706055,8.520000457763672,8.979999542236328,11688,0.0,0.0,8.805999851226806,8.569000017642974,9.041833321253458,1.9759220298565088,2.7657816909308672,-5.229396371409063,54.280817252284464,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-03-25,8.979999542236328,9.100000381469727,8.520000457763672,8.960000038146973,31463,0.0,0.0,8.827999877929688,8.583000028133393,9.054833320776622,1.4952442460640436,2.8544780262522895,-5.210844594572397,53.85870038783116,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-03-26,8.899999618530273,8.9399995803833,8.5,8.9399995803833,52786,0.0,0.0,8.787999820709228,8.601500022411347,9.066833317279816,1.729628616012033,2.1682241215131364,-5.132258183037552,53.41137302948128,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-03-27,8.800000190734863,9.15999984741211,8.319999694824219,8.979999542236328,29699,0.0,0.0,8.795999813079835,8.623000013828278,9.05983331600825,2.0918569016211435,2.0062599904224188,-4.821648334391652,54.230127377125285,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-03-28,9.100000381469727,9.100000381469727,8.739999771118164,9.100000381469727,9364,0.0,0.0,8.835999870300293,8.647000014781952,9.054833320776622,2.9877831037186415,2.185727479995932,-4.504039903847621,56.68924258701279,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-04-02,9.100000381469727,9.100000381469727,8.579999923706055,8.800000190734863,4539,0.0,0.0,8.865999889373779,8.654500019550323,9.046166654427847,-0.7444134836728155,2.4438138465039265,-4.3296420444102015,49.52535589518598,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-04-03,8.800000190734863,8.800000190734863,8.399999618530273,8.800000190734863,37490,0.0,0.0,8.863999938964843,8.662000024318695,9.034499990940095,-0.7220188252557022,2.33202394457435,-4.123083369250614,49.52535589518598,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-04-04,8.520000457763672,8.899999618530273,8.5,8.880000114440918,12567,0.0,0.0,8.901999950408936,8.676500022411346,9.023083325227102,-0.2471336339089393,2.598973404196671,-3.841073946937449,51.42384705690476,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-04-05,8.880000114440918,8.880000114440918,8.5600004196167,8.65999984741211,5513,0.0,0.0,8.907999897003174,8.689000022411346,9.010666660467784,-2.7840149579985614,2.520426677718574,-3.5698428338013692,46.26976929339664,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-04-08,8.65999984741211,8.9399995803833,8.65999984741211,8.699999809265137,15903,0.0,0.0,8.879999923706055,8.706500017642975,9.002499989668529,-2.0270283331916503,1.992762943909694,-3.2879752553762813,47.30392451354305,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-04-09,8.800000190734863,8.880000114440918,8.5600004196167,8.699999809265137,13001,0.0,0.0,8.851999950408935,8.72150000333786,8.993833323319754,-1.717127677308405,1.4963016341355262,-3.028000522044042,47.30392451354305,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-04-10,8.760000228881836,8.880000114440918,8.479999542236328,8.479999542236328,16513,0.0,0.0,8.803999900817871,8.732999980449677,8.987833321094513,-3.680149502857719,0.813007220051988,-2.835314491722278,42.131364422712856,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-04-11,8.479999542236328,8.739999771118164,8.319999694824219,8.5600004196167,27551,0.0,0.0,8.76599998474121,8.743499982357026,8.98016666173935,-2.3499836354447874,0.2573340473447218,-2.6354374957277766,44.50764518229686,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-04-12,8.5600004196167,8.899999618530273,8.34000015258789,8.699999809265137,35525,0.0,0.0,8.738000011444091,8.75649996995926,8.973833326498667,-0.4348844372761061,-0.2112711537558998,-2.421856397729698,48.49359496826233,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-04-15,8.699999809265137,9.479999542236328,8.420000076293945,8.979999542236328,40203,0.0,0.0,8.725999927520752,8.782499957084656,8.969833322366078,2.9108367731529814,-0.6433251333901516,-2.0884821216723193,55.39446130567795,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-04-16,8.600000381469727,8.9399995803833,8.520000457763672,8.9399995803833,15451,0.0,0.0,8.739999866485595,8.805999946594238,8.966166651248932,2.2883262809262086,-0.7494898990337613,-1.786345390227425,54.275707530358105,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-04-17,8.9399995803833,8.9399995803833,8.5,8.819999694824219,13406,0.0,0.0,8.74199981689453,8.82199993133545,8.96149998108546,0.8922429600026753,-0.906825153747296,-1.5566595998933805,50.95119134389184,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-04-18,8.960000038146973,8.960000038146973,8.479999542236328,8.84000015258789,23111,0.0,0.0,8.737999820709229,8.842999935150146,8.958999979496003,1.167318997156752,-1.1873811513166634,-1.2947878626112255,51.484583360041654,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-04-19,8.819999694824219,8.979999542236328,8.5,8.979999542236328,12462,0.0,0.0,8.769999790191651,8.859999918937683,8.956499977906544,2.394524025867598,-1.0158028168111248,-1.0774304606364355,55.160375185048935,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-04-22,8.899999618530273,8.899999618530273,8.640000343322754,8.739999771118164,6062,0.0,0.0,8.773999786376953,8.863999915122985,8.952833306789397,-0.38750873132660896,-1.0153444224709656,-0.9922377489039742,48.39159449520711,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-04-23,8.739999771118164,9.020000457763672,8.5,9.0,23425,0.0,0.0,8.80399980545044,8.872499918937683,8.949499976634979,2.226263049531408,-0.7720497504996828,-0.860383908579526,54.85472754137645,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-04-24,8.979999542236328,8.979999542236328,8.699999809265137,8.9399995803833,12202,0.0,0.0,8.849999809265137,8.870499897003175,8.94666664203008,1.0169465882241286,-0.23110408630930995,-0.8513421598730975,53.19899078805408,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-04-25,8.9399995803833,8.960000038146973,8.720000267028809,8.9399995803833,7660,0.0,0.0,8.887999725341796,8.866499876976013,8.94399996995926,0.5850568929839264,0.2424840541825623,-0.8665037258894309,53.19899078805409,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-04-26,8.899999618530273,9.119999885559082,8.5,8.779999732971191,50199,0.0,0.0,8.895999717712403,8.853499865531921,8.941333297888438,-1.3039567043853384,0.4800344815719791,-0.9823303687522661,48.65689522027288,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-04-29,8.779999732971191,9.100000381469727,8.65999984741211,8.899999618530273,6964,0.0,0.0,8.887999725341796,8.845499849319458,8.939666624863943,0.1350123037724982,0.4804689022249919,-1.0533589170157474,51.96911687959159,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-04-30,8.899999618530273,9.100000381469727,8.619999885559082,8.920000076293945,4942,0.0,0.0,8.885999774932861,8.843499851226806,8.93566662867864,0.38262775402041055,0.4805781016681906,-1.0314482543029078,52.518913043165036,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-05-02,8.920000076293945,9.100000381469727,8.640000343322754,9.0,40570,0.0,0.0,8.90399980545044,8.843499851226806,8.926499958833059,1.0781693244287314,0.6841177728435278,-0.9298169270042029,54.750085874498275,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-05-03,8.979999542236328,9.220000267028809,8.720000267028809,9.199999809265137,13094,0.0,0.0,8.939999771118163,8.848999857902527,8.922166621685028,2.908277906079343,1.0283638227699798,-0.8200560120080194,59.83189756974115,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-05-06,9.199999809265137,9.5,9.199999809265137,9.420000076293945,26905,0.0,0.0,8.983999824523925,8.860499858856201,8.917333288987477,4.853075025445296,1.3938261682187627,-0.6373366149885018,64.54835108665645,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-05-07,9.520000457763672,9.539999961853027,9.0,9.420000076293945,22443,0.0,0.0,9.051999855041505,8.875999855995179,8.912999959786733,4.065402420963178,1.9828751904209279,-0.4151251425837465,64.54835108665645,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-05-08,9.420000076293945,9.5,9.020000457763672,9.260000228881836,5624,0.0,0.0,9.077999877929688,8.884999871253967,8.905999958515167,2.004850775495432,2.1722004442582197,-0.23579707342263612,58.73170574612852,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-05-10,9.100000381469727,9.380000114440918,8.880000114440918,9.199999809265137,26509,0.0,0.0,9.103999900817872,8.896499872207642,8.898499953746796,1.0544805524288354,2.3323782565147124,-0.022476614592919227,56.66938901739275,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-05-13,9.199999809265137,9.479999542236328,8.920000076293945,9.199999809265137,42448,0.0,0.0,9.129999923706055,8.892999863624572,8.892666622002919,0.7667019292883731,2.665018145911536,0.003747375627791788,56.66938901739275,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-05-14,9.199999809265137,9.359999656677246,8.979999542236328,9.359999656677246,20697,0.0,0.0,9.18799991607666,8.904499864578247,8.892166618506113,1.8720041594649006,3.1837841070239654,0.13869787422185362,60.91400645510103,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-05-15,9.359999656677246,9.359999656677246,9.020000457763672,9.300000190734863,3377,0.0,0.0,9.22799997329712,8.91949987411499,8.891999955972036,0.7802364287612595,3.4587152142623867,0.30926583759691545,58.59595086438379,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-05-16,9.300000190734863,9.300000190734863,8.920000076293945,9.020000457763672,28527,0.0,0.0,9.238000011444091,8.932499885559082,8.88899995883306,-2.3598133081874906,3.420096611239847,0.48936806083339657,49.18862332200147,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-05-17,8.920000076293945,9.279999732971191,8.920000076293945,9.0,26201,0.0,0.0,9.238000011444091,8.936999893188476,8.886499957243602,-2.5763153404335952,3.368021952031451,0.5682770065588103,48.58855644108809,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-05-20,8.920000076293945,9.279999732971191,8.619999885559082,9.279999732971191,19990,0.0,0.0,9.246000003814697,8.956499886512756,8.885666620731353,0.367723655012625,3.232290749401871,0.7971632158260346,56.575368987925664,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-05-21,9.520000457763672,9.520000457763672,9.0,9.220000267028809,9629,0.0,0.0,9.226000022888183,8.971999883651733,8.884333288669586,-0.06503095430836642,2.831031459321283,0.986754910398859,54.61734186260841,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-05-22,9.0,9.15999984741211,8.960000038146973,9.0,13849,0.0,0.0,9.184000015258789,8.972499895095826,8.879499955972035,-2.0034844833741463,2.357203930184101,1.047355589671945,48.050590876574844,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-05-23,8.9399995803833,9.079999923706055,8.920000076293945,8.979999542236328,11411,0.0,0.0,9.155999946594239,8.972499895095826,8.874666615327198,-1.9222412121504853,2.0451385192961693,1.1023882249239898,47.49155740577856,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-05-24,8.979999542236328,8.979999542236328,8.680000305175781,8.979999542236328,29918,0.0,0.0,9.133999919891357,8.972999882698058,8.869499941666922,-1.6860124699547914,1.7942721419593755,1.1669196878272392,47.49155740577856,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-05-27,8.979999542236328,9.199999809265137,8.979999542236328,9.199999809265137,19138,0.0,0.0,9.133999919891357,8.979499888420104,8.867833276589712,0.7225737897156088,1.7205861505772149,1.2592321973980054,54.27765653156023,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-05-28,9.399999618530273,9.399999618530273,8.9399995803833,9.039999961853027,15307,0.0,0.0,9.101999950408935,8.980999898910522,8.86583327849706,-0.6811688518315357,1.347289309212569,1.2989937527111324,49.288598295689425,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-05-29,9.039999961853027,9.180000305175781,8.899999618530273,9.0,19401,0.0,0.0,9.07199993133545,8.97849988937378,8.863666609923046,-0.7936500427734327,1.0413771021184655,1.2955505267106453,48.09831045223924,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-05-30,9.0,11.75,9.0,10.300000190734863,120751,0.0,0.0,9.199999904632568,9.015999889373779,8.873666608333588,11.956524972879631,2.040816520812636,1.6039962658335676,71.87248413493656,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-05-31,10.0,10.300000190734863,9.380000114440918,10.25,96022,0.0,0.0,9.324999904632568,9.052249884605407,8.880583274364472,9.919572169731616,3.0130633102717312,1.933055576839015,70.5342354444702,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-06-03,10.300000190734863,10.899999618530273,9.600000381469727,10.0,29507,0.0,0.0,9.396999931335449,9.080249881744384,8.88874993721644,6.4169423546952835,3.4883406703143987,2.1544080537821206,64.10688638376617,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-06-04,10.199999809265137,10.600000381469727,9.699999809265137,10.100000381469727,66768,0.0,0.0,9.484999942779542,9.116249895095825,8.896583275000255,6.483926646286951,4.044975202819852,2.4691121670590266,65.46259981149704,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-06-05,10.100000381469727,10.399999618530273,9.899999618530273,10.199999809265137,83036,0.0,0.0,9.604999923706055,9.153749895095824,8.906583273410797,6.194689123219723,4.929674000072805,2.775100328572732,66.81253042344422,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-06-07,10.100000381469727,10.600000381469727,9.899999618530273,10.100000381469727,65205,0.0,0.0,9.717000007629395,9.18874990940094,8.913416612148286,3.941549588758008,5.748878829404269,3.0889759699708943,64.11380894771634,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-06-10,10.0,10.199999809265137,9.800000190734863,10.199999809265137,26769,0.0,0.0,9.839000034332276,9.23174991607666,8.921083279450734,3.6690697598656925,6.577844111636061,3.482386913050475,65.60976875152754,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-06-11,10.199999809265137,10.399999618530273,9.850000381469727,10.100000381469727,34348,0.0,0.0,9.929000091552734,9.270249915122985,8.927916618188222,1.7222307215252652,7.106067068969728,3.8344141368586624,62.79090561920641,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-06-12,10.100000381469727,11.100000381469727,10.100000381469727,10.399999618530273,58809,0.0,0.0,10.065000057220459,9.312749910354615,8.937249950567882,3.3283612459544054,8.077637154514756,4.201515699612648,67.3262638759988,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-06-13,10.600000381469727,10.600000381469727,9.899999618530273,10.300000190734863,58602,0.0,0.0,10.195000076293946,9.345749926567077,8.946249949932099,1.0299177406096394,9.087019836821367,4.465557958594819,64.50391547098053,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-06-14,10.300000190734863,10.300000190734863,9.899999618530273,10.199999809265137,32157,0.0,0.0,10.185000038146972,9.377249932289123,8.955083278814952,0.14727315721143022,8.613933847241134,4.7142683136503205,61.71763881107773,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-06-17,10.199999809265137,10.199999809265137,9.75,10.100000381469727,33292,0.0,0.0,10.170000076293945,9.409249949455262,8.963249949614207,-0.6882959124787674,8.08513038685646,4.975873732721817,58.974287638667136,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-06-18,10.100000381469727,10.100000381469727,9.399999618530273,10.100000381469727,49203,0.0,0.0,10.180000114440919,9.440749955177306,8.970749954382578,-0.7858519849887611,7.830417739834402,5.239249819521659,58.97428763866714,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-06-19,10.100000381469727,10.100000381469727,9.850000381469727,9.899999618530273,11215,0.0,0.0,10.160000038146972,9.463749957084655,8.976083282629649,-2.5590592385875484,7.357021098608986,5.432956213750044,53.46212729999064,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-06-20,9.850000381469727,9.949999809265137,9.699999809265137,9.949999809265137,34506,0.0,0.0,10.135000038146973,9.49399995803833,8.983666614691417,-1.8253599228960737,6.751633483692242,5.680679896472788,54.6044713097737,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-06-24,9.899999618530273,9.899999618530273,9.600000381469727,9.899999618530273,77528,0.0,0.0,10.114999961853027,9.516499948501586,8.98966660896937,-2.125559507005337,6.289077040826095,5.8604324548206455,53.19819089532131,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-06-25,9.899999618530273,10.199999809265137,9.699999809265137,9.899999618530273,16990,0.0,0.0,10.084999942779541,9.540499949455262,8.995166607697804,-1.8344107615163727,5.707248008060304,6.062515187776253,53.19819089532131,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-06-26,9.800000190734863,10.100000381469727,9.75,9.800000190734863,17548,0.0,0.0,10.054999923706054,9.561999964714051,9.002333279450735,-2.536049079125241,5.155824731345796,6.2169069716719445,50.19945678324149,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-06-27,9.800000190734863,10.0,9.75,9.75,16777,0.0,0.0,9.989999961853027,9.58624997138977,9.010416615009309,-2.4024020297244273,4.211761550848876,6.390751737508504,48.72064482583002,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-06-28,9.850000381469727,10.399999618530273,9.5,9.800000190734863,84335,0.0,0.0,9.939999961853028,9.608749985694885,9.017249953746795,-1.408448406996427,3.4473784483027856,6.559649948511338,50.297447374115094,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-07-01,9.800000190734863,10.100000381469727,9.800000190734863,10.100000381469727,13593,0.0,0.0,9.930000019073486,9.63824999332428,9.02708328962326,1.7119875334310701,3.027002058997017,6.7703673943450084,58.53583520237599,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-07-02,10.0,10.0,9.600000381469727,9.800000190734863,34449,0.0,0.0,9.9,9.658249998092652,9.031083293755849,-1.0100990834862331,2.5030414614975833,6.9445346027362,49.6696062898949,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-07-03,9.800000190734863,9.800000190734863,9.600000381469727,9.699999809265137,13195,0.0,0.0,9.859999942779542,9.670749998092651,9.038249957561494,-1.6227194162569218,1.9569314140497502,6.998036605548857,47.108200176991296,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-07-04,9.649999618530273,9.800000190734863,9.199999809265137,9.75,61986,0.0,0.0,9.844999980926513,9.678999996185302,9.044499957561493,-0.9649566390102979,1.715053051003561,7.015313633711133,48.53721168080335,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-07-05,9.449999809265137,10.300000190734863,9.399999618530273,9.449999809265137,29996,0.0,0.0,9.794999980926514,9.679749989509583,9.048249955972036,-3.522206966137672,1.1906298359134604,6.9792505358535495,41.32321362548092,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-07-08,9.449999809265137,9.600000381469727,9.100000381469727,9.300000190734863,47366,0.0,0.0,9.735000038146973,9.680749988555908,9.050083291530608,-4.468411358064161,0.560390978541919,6.96862864914735,38.26116101271379,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-07-09,9.100000381469727,9.300000190734863,9.050000190734863,9.199999809265137,32422,0.0,0.0,9.665000057220459,9.680749988555908,9.051416623592377,-4.811176877416911,-0.1626932970489682,6.952871480064046,36.32847242478817,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-07-10,9.100000381469727,9.350000381469727,8.600000381469727,8.899999618530273,78014,0.0,0.0,9.575,9.673249983787537,9.050749957561493,-7.04961233910941,-1.0156874261722342,6.877883370382731,31.23161245090793,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-07-11,9.0,9.199999809265137,8.699999809265137,9.0,20560,0.0,0.0,9.5,9.664249992370605,9.050916628042858,-5.263157894736842,-1.6995627441371186,6.776477892056031,34.52899534232047,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-07-12,8.850000381469727,9.100000381469727,8.600000381469727,9.050000190734863,14475,0.0,0.0,9.425,9.657999992370605,9.05099996328354,-3.978777817136736,-2.4125076884931094,6.706441625780955,36.17682987046394,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-07-15,9.050000190734863,9.050000190734863,8.600000381469727,8.949999809265137,12057,0.0,0.0,9.309999942779541,9.656249976158142,9.048916629950206,-3.8668113397101127,-3.585760872321168,6.7116691538275095,34.31653128694538,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-07-16,8.600000381469727,9.350000381469727,7.650000095367432,9.050000190734863,580299,0.0,0.0,9.234999942779542,9.657499980926513,9.049499968687693,-2.00324583855923,-4.37483861228481,6.718603396238135,37.763083775691754,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-07-17,9.050000190734863,9.350000381469727,9.0,9.100000381469727,90430,0.0,0.0,9.175,9.652999997138977,9.051833307743072,-0.817434534389909,-4.951828418943844,6.641380469099646,39.473221412643284,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-07-18,9.100000381469727,9.399999618530273,8.5,8.949999809265137,183973,0.0,0.0,9.094999980926513,9.646249985694885,9.054749969641367,-1.5942844636114555,-5.714656012293482,6.532483150133246,36.254721437475816,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-07-19,8.949999809265137,9.300000190734863,8.800000190734863,9.100000381469727,21539,0.0,0.0,9.060000038146972,9.64874999523163,9.058916636308034,0.4415048913281845,-6.101826219723949,6.511080547529822,41.400265169608915,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-07-22,8.949999809265137,9.100000381469727,8.600000381469727,8.75,36720,0.0,0.0,9.005000019073487,9.64300000667572,9.061499973138174,-2.8317603390713075,-6.61619814539619,6.417260224701645,34.418897765349826,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-07-23,8.899999618530273,9.0,8.75,9.0,22992,0.0,0.0,8.985000038146973,9.643500018119813,9.066499976317088,0.1669444829086558,-6.828433439472602,6.364088052831039,41.94903650260532,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-07-24,8.800000190734863,9.0,8.75,8.899999618530273,28052,0.0,0.0,8.985000038146973,9.63600001335144,9.072333308060964,-0.9460258125299874,-6.755915050876454,6.213029064856404,39.971948864250415,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-07-25,8.75,8.850000381469727,8.550000190734863,8.699999809265137,29965,0.0,0.0,8.955000019073486,9.627500009536742,9.077166640758515,-2.8475735261330843,-6.985198543724707,6.062832054962034,36.288261987341144,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-07-26,8.649999618530273,8.800000190734863,8.350000381469727,8.699999809265137,61434,0.0,0.0,8.919999980926514,9.620000004768372,9.081833302974701,-2.4663696427331834,-7.2765075207368675,5.9257496128826475,36.288261987341144,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-07-29,8.5,8.649999618530273,8.300000190734863,8.5,32078,0.0,0.0,8.875,9.575,9.081833302974701,-4.225352112676056,-7.310704960835503,5.430254889877405,32.78427609449152,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-07-30,8.300000190734863,8.699999809265137,8.25,8.699999809265137,61319,0.0,0.0,8.839999961853028,9.536249995231628,9.08349996805191,-1.58371214018133,-7.3010883075290955,4.98431253120615,39.115499143856894,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-07-31,8.699999809265137,9.100000381469727,8.699999809265137,8.949999809265137,49637,0.0,0.0,8.824999904632568,9.509999990463257,9.088916631539663,1.4164295295567273,-7.20294517894443,4.63293235040118,45.96679291486873,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-08-01,9.100000381469727,9.100000381469727,8.600000381469727,9.0,6664,0.0,0.0,8.829999923706055,9.482499980926514,9.095916632811228,1.9252556938029315,-6.881097374457417,4.25007576169711,47.24541553137233,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-08-02,8.600000381469727,8.899999618530273,8.600000381469727,8.800000190734863,16485,0.0,0.0,8.799999904632568,9.447499990463257,9.102583301067352,3.251162485601908e-06,-6.853665906158303,3.7892176098565447,42.87494846920556,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-08-05,8.550000190734863,8.699999809265137,8.0,8.100000381469727,73082,0.0,0.0,8.734999942779542,9.397499990463256,9.102583301067352,-7.269600062616069,-7.049747787773672,3.2399229937431406,31.79041537178321,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-08-06,8.25,8.600000381469727,8.0,8.149999618530273,16960,0.0,0.0,8.649999904632569,9.346249985694886,9.103666627407074,-5.780350192079388,-7.449512715024509,2.6646775218844403,33.12043296414575,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-08-07,8.149999618530273,8.449999809265137,8.100000381469727,8.449999809265137,13715,0.0,0.0,8.604999923706055,9.30499997138977,9.106249956289927,-1.8012796724600308,-7.5228377198927125,2.182567094620126,40.604051460076406,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-08-08,8.449999809265137,8.649999618530273,8.149999618530273,8.649999618530273,19730,0.0,0.0,8.599999904632568,9.26124997138977,9.110166617234547,0.5813920285135317,-7.139965650424748,1.6584038525640568,45.020862722040235,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-08-09,8.399999618530273,8.75,8.399999618530273,8.699999809265137,4860,0.0,0.0,8.599999904632568,9.221249961853028,9.116499948501588,1.1627896016452435,-6.737156673883482,1.1490156742517952,46.099977715705684,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-08-12,8.350000381469727,8.600000381469727,8.0,8.199999809265137,24249,0.0,0.0,8.569999885559081,9.171249961853027,9.118166613578797,-4.317387178935848,-6.555813861739569,0.5821712908292116,38.05592183026582,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-08-13,8.199999809265137,8.600000381469727,8.100000381469727,8.199999809265137,23748,0.0,0.0,8.519999885559082,9.123749947547912,9.118333276112875,-3.755869490518746,-6.617345559224725,0.05940418353897645,38.05592183026582,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-08-14,8.399999618530273,8.449999809265137,8.25,8.449999809265137,6237,0.0,0.0,8.469999885559082,9.082499933242797,9.122083274523417,-0.23612841280014735,-6.743738532184384,-0.43392874291303996,43.74777204525026,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-08-15,8.449999809265137,8.649999618530273,8.0,8.100000381469727,52084,0.0,0.0,8.379999923706055,9.037499952316285,9.120416609446208,-3.341283350662598,-7.275242401984347,-0.9091323420910881,38.424551232661564,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-08-16,8.100000381469727,8.149999618530273,8.0,8.149999618530273,7181,0.0,0.0,8.314999866485596,8.992499947547913,9.116833273569743,-1.9843686182169682,-7.534057103298153,-1.363777556207811,39.55604493624902,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-08-19,8.100000381469727,8.100000381469727,7.349999904632568,7.75,40811,0.0,0.0,8.279999828338623,8.938749957084656,9.109249941507976,-6.400964243074952,-7.369600133225821,-1.8717236382592235,34.149607782327834,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-08-20,7.650000095367432,7.900000095367432,7.449999809265137,7.75,38698,0.0,0.0,8.239999866485595,8.884999966621399,9.098666604359945,-5.94660041778111,-7.259427153167118,-2.348329123699955,34.149607782327834,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-08-21,7.849999904632568,7.900000095367432,7.75,7.75,8427,0.0,0.0,8.169999885559083,8.833749961853027,9.08741660118103,-5.140757545192323,-7.513797415143402,-2.7914054176303043,34.149607782327834,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-08-22,7.849999904632568,7.900000095367432,7.449999809265137,7.699999809265137,21568,0.0,0.0,8.074999904632568,8.782499957084656,9.074083264668783,-4.643964084164217,-8.055793406310958,-3.213363808545232,33.43613002774276,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-08-23,7.699999809265137,7.900000095367432,7.349999904632568,7.699999809265137,19207,0.0,0.0,7.974999904632568,8.729999947547913,9.061416594187419,-3.4482770991343568,-8.648339604256353,-3.6574485147509677,33.43613002774276,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-08-26,7.699999809265137,7.900000095367432,7.650000095367432,7.849999904632568,17109,0.0,0.0,7.939999914169311,8.673749935626983,9.051833260059357,-1.1335013918090033,-8.459432505009525,-4.1768701827578205,37.94686862358024,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-08-27,7.849999904632568,7.949999809265137,7.699999809265137,7.949999809265137,27313,0.0,0.0,7.914999914169312,8.627499926090241,9.043083258469899,0.4421970369597698,-8.258476013036791,-4.595593344674956,40.82581841153015,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-08-28,8.0,8.5,7.099999904632568,8.449999809265137,66649,0.0,0.0,7.914999914169312,8.596249926090241,9.038666594028474,6.759316499019493,-7.924967489059227,-4.894711662785763,52.653799534294556,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-08-29,8.449999809265137,8.449999809265137,7.800000190734863,8.100000381469727,44825,0.0,0.0,7.914999914169312,8.554999935626984,9.031499930222829,2.3373401049471885,-7.481005567193706,-5.275978500551103,45.75878949189912,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-08-30,8.0,8.25,7.75,8.199999809265137,30715,0.0,0.0,7.9199999332427975,8.523749935626984,9.026499927043915,3.5353519997782996,-7.083150103461788,-5.569711355235959,47.85963500924512,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-09-02,8.199999809265137,8.199999809265137,7.5,7.900000095367432,25007,0.0,0.0,7.934999942779541,8.488749933242797,9.018166597684225,-0.4410818861310454,-6.523339653282936,-5.870557598452178,42.53685920649434,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-09-03,7.900000095367432,7.900000095367432,7.849999904632568,7.849999904632568,1310,0.0,0.0,7.944999933242798,8.454999935626983,9.010749932130178,-1.1957209491310175,-6.031933841125049,-6.167633112550639,41.70435637623846,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-09-04,7.849999904632568,7.849999904632568,7.550000190734863,7.699999809265137,18667,0.0,0.0,7.939999914169311,8.424999940395356,8.997083262602489,-3.0226713790749886,-5.7566769098788315,-6.358542046454872,39.22420060857313,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-09-05,7.650000095367432,7.75,7.449999809265137,7.699999809265137,721,0.0,0.0,7.939999914169311,8.392499935626983,8.987083264191945,-3.0226713790749886,-5.391719093577409,-6.615976630972304,39.224200608573135,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-09-06,7.699999809265137,7.75,7.400000095367432,7.550000190734863,15419,0.0,0.0,7.924999952316284,8.354999935626983,8.977499934037526,-4.73185821877283,-5.1466186310440785,-6.934001704086684,36.69342428118313,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-09-09,7.550000190734863,8.199999809265137,7.449999809265137,7.699999809265137,15398,0.0,0.0,7.909999942779541,8.323749935626983,8.970833265781403,-2.6548689637614684,-4.970716276284639,-7.213190915304072,40.806426151444725,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-09-10,7.699999809265137,7.949999809265137,7.5,7.75,9732,0.0,0.0,7.889999961853027,8.291249930858612,8.961916601657867,-1.7743974972104681,-4.839438834333065,-7.483518321016157,42.15550795804244,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-09-11,7.699999809265137,7.900000095367432,7.449999809265137,7.849999904632568,18683,0.0,0.0,7.82999997138977,8.259999918937684,8.956499934196472,0.2554269899856485,-5.205810554090364,-7.7764754131187805,44.86212229488868,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-09-12,7.599999904632568,8.199999809265137,7.5,8.149999618530273,45246,0.0,0.0,7.834999895095825,8.239999914169312,8.952749927838644,4.02041771093854,-4.9150488263605245,-7.96124117633433,52.10281757560251,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-09-13,8.100000381469727,8.100000381469727,7.699999809265137,7.699999809265137,18920,0.0,0.0,7.784999895095825,8.204999899864196,8.942083263397217,-1.0918444056015242,-5.118830102305339,-8.242859542027938,42.98443828213506,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-09-16,7.599999904632568,7.699999809265137,7.400000095367432,7.550000190734863,13589,0.0,0.0,7.749999904632569,8.174999904632568,8.930166602134705,-2.5806415014038313,-5.198776819057357,-8.456356204167777,40.44364549830267,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-09-17,7.400000095367432,7.550000190734863,7.349999904632568,7.400000095367432,6104,0.0,0.0,7.704999923706055,8.134999907016754,8.917166602611541,-3.958466338204973,-5.285801944998271,-8.77147114606692,38.02321356347574,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-09-18,7.400000095367432,8.050000190734863,7.400000095367432,7.5,6004,0.0,0.0,7.684999942779541,8.099999916553497,8.905166606108347,-2.407286195927147,-5.1234565191271715,-9.041567947786175,40.57646619531719,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-09-19,7.400000095367432,7.599999904632568,7.25,7.349999904632568,34635,0.0,0.0,7.649999952316284,8.066249918937682,8.891583275794982,-3.9215692752113127,-5.160390154093047,-9.282186661896928,38.04463476856878,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-09-20,7.449999809265137,7.900000095367432,7.25,7.300000190734863,51888,0.0,0.0,7.624999952316284,8.031249928474427,8.876583274205526,-4.262291981820856,-5.058365506940608,-9.523183860478774,37.211156276407316,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-09-23,7.25,7.300000190734863,7.050000190734863,7.25,24113,0.0,0.0,7.57999997138977,7.999999928474426,8.863666605949401,-4.353561644265625,-5.249999510496851,-9.743898500145203,36.353456082307765,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-09-24,7.0,7.25,7.0,7.25,63724,0.0,0.0,7.5299999713897705,7.963749933242798,8.850749937693278,-3.7184591295302813,-5.446554267637663,-10.02174969007942,36.35345608230776,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-09-25,7.5,7.5,7.050000190734863,7.300000190734863,7950,0.0,0.0,7.475,7.922499942779541,8.837583271662394,-2.3411345721088477,-5.648468867297204,-10.354452125130829,38.01055880651582,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-09-26,7.300000190734863,7.300000190734863,7.050000190734863,7.150000095367432,19590,0.0,0.0,7.375000047683716,7.8762499451637265,8.824999940395355,-3.0508467913427375,-6.364067938039403,-10.750708233875915,35.06133575006042,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-09-27,7.050000190734863,7.5,7.050000190734863,7.449999809265137,35339,0.0,0.0,7.350000047683716,7.842499935626984,8.814583273728688,1.3605409650702591,-6.279883863383086,-11.02812586726519,44.35970482022732,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-09-30,7.400000095367432,8.050000190734863,7.099999904632568,7.400000095367432,63026,0.0,0.0,7.335000038146973,7.824999928474426,8.803749942779541,0.8861630113485293,-6.2619794863433915,-11.11742178806253,43.24822126547728,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-10-01,7.400000095367432,7.800000190734863,7.400000095367432,7.550000190734863,33939,0.0,0.0,7.350000047683716,7.809999942779541,8.795999948183695,2.7210903639949673,-5.889883463073536,-11.20964087326712,47.498295323728506,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-10-02,7.150000095367432,7.849999904632568,7.150000095367432,7.449999809265137,9892,0.0,0.0,7.3450000286102295,7.784999942779541,8.786749943097432,1.4295409155331829,-5.651893608263977,-11.40068861416537,45.07478174544632,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-10-03,7.199999809265137,7.5,7.099999904632568,7.5,16634,0.0,0.0,7.360000038146973,7.756249952316284,8.77674994468689,1.9021733848832256,-5.108782164130451,-11.627310779070072,46.543447829710054,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-10-04,8.050000190734863,8.050000190734863,7.199999809265137,7.699999809265137,1172,0.0,0.0,7.4,7.7312499523162845,8.766083280245462,4.054051476555896,-4.284558827606415,-11.80496802102251,52.06483389651245,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-10-07,7.699999809265137,7.699999809265137,7.099999904632568,7.300000190734863,29679,0.0,0.0,7.405000019073486,7.7087499618530275,8.752416618665059,-1.4179585154377954,-3.9403268270816505,-11.924325615240356,42.590037750150074,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-10-08,7.599999904632568,7.599999904632568,7.050000190734863,7.050000190734863,28628,0.0,0.0,7.3850000381469725,7.679999971389771,8.737666622797649,-4.536219982148661,-3.8411449784083174,-12.104680769672482,37.94256178517293,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-10-09,7.050000190734863,7.300000190734863,7.0,7.199999809265137,16461,0.0,0.0,7.375,7.648749971389771,8.723999953269958,-2.3728839421676375,-3.579015818450538,-12.325194723060019,42.02996532627452,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-10-10,7.25,7.25,6.900000095367432,7.050000190734863,27357,0.0,0.0,7.365000009536743,7.622499966621399,8.70791662534078,-4.276983277583096,-3.378156224496391,-12.464711198092147,39.24617995955666,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-10-11,7.0,7.199999809265137,6.900000095367432,7.199999809265137,20202,0.0,0.0,7.340000009536743,7.59874997138977,8.695083292325338,-1.907359674246677,-3.4051648340484006,-12.608658066602299,43.291123312289855,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-10-14,7.199999809265137,7.199999809265137,7.0,7.199999809265137,4843,0.0,0.0,7.3199999809265135,7.584999966621399,8.680083290735881,-1.6393466116674498,-3.493737466856242,-12.61604626862565,43.291123312289855,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-10-15,7.5,7.5,7.150000095367432,7.349999904632568,42400,0.0,0.0,7.299999952316284,7.574999964237213,8.666833293437957,0.6849308581217077,-3.630363210815151,-12.597834667333679,47.35609649854695,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-10-16,7.349999904632568,7.349999904632568,7.150000095367432,7.25,13816,0.0,0.0,7.2799999713897705,7.5624999642372135,8.65274996360143,-0.4120875207097485,-3.7355371131685975,-12.600040495223494,45.03826923329262,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-10-17,7.199999809265137,7.25,7.050000190734863,7.199999809265137,24627,0.0,0.0,7.249999952316284,7.549999964237213,8.639583297570546,-0.6896571500689902,-3.973510110489628,-12.611526456834138,43.8817681406653,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-10-18,7.25,7.300000190734863,7.050000190734863,7.099999904632568,11457,0.0,0.0,7.189999961853028,7.534999966621399,8.624583299954732,-1.2517393282052849,-4.578633129351757,-12.633460602543572,41.58200861253314,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-10-21,7.099999904632568,7.449999809265137,7.050000190734863,7.150000095367432,11814,0.0,0.0,7.174999952316284,7.51749997138977,8.609833300113678,-0.3484300643205149,-4.556036187256116,-12.687043879345323,43.18531193881909,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-10-22,7.199999809265137,7.400000095367432,7.0,7.400000095367432,21733,0.0,0.0,7.209999942779541,7.503749978542328,8.596499967575074,2.635230986071866,-3.914709799803995,-12.71156858203295,50.50046214930959,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-10-23,7.25,7.300000190734863,6.849999904632568,7.050000190734863,71547,0.0,0.0,7.1949999809265135,7.468749988079071,8.57858330408732,-2.015285484031069,-3.665272068143824,-12.937256382175164,42.2908658831967,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-10-24,7.050000190734863,7.199999809265137,6.849999904632568,7.099999904632568,9219,0.0,0.0,7.1999999523162845,7.443749976158142,8.559249969323476,-1.3888895603609765,-3.274559524736505,-13.032683905287357,43.698945630524605,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-10-25,7.099999904632568,7.349999904632568,7.0,7.349999904632568,14762,0.0,0.0,7.214999961853027,7.422499978542328,8.541999967892965,1.8711010879183592,-2.7955542915346845,-13.105829940980213,50.236971965628534,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-10-28,7.349999904632568,7.5,7.050000190734863,7.199999809265137,28691,0.0,0.0,7.214999961853027,7.4049999713897705,8.524833297729492,-0.2079023238697005,-2.5658340347175472,-13.136131666504003,46.7305270062361,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-10-29,7.150000095367432,7.150000095367432,6.800000190734863,7.099999904632568,15341,0.0,0.0,7.189999961853028,7.386249971389771,8.507333298524221,-1.2517393282052849,-2.6569640926980065,-13.177846544803018,44.50054364608677,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-10-30,6.949999809265137,7.400000095367432,6.949999809265137,7.199999809265137,17701,0.0,0.0,7.184999942779541,7.3737499713897705,8.490666631857554,0.2087664106479165,-2.559756288761914,-13.154640370368998,47.21329613939633,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-10-31,7.099999904632568,7.199999809265137,7.0,7.199999809265137,6705,0.0,0.0,7.184999942779541,7.36124997138977,8.47266663312912,0.2087664106479165,-2.3942948452401773,-13.117672509308692,47.21329613939633,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-11-01,7.199999809265137,7.199999809265137,6.949999809265137,7.199999809265137,6645,0.0,0.0,7.194999933242798,7.352499961853027,8.455166629950206,0.06949098080235026,-2.142128927948138,-13.041335746019147,47.21329613939633,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-11-04,7.0,7.099999904632568,6.650000095367432,7.0,52625,0.0,0.0,7.179999923706054,7.334999966621399,8.438333292802175,-2.506962752349793,-2.113156695578549,-13.07525180502067,42.075943777661905,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-11-05,6.75,7.300000190734863,6.699999809265137,7.099999904632568,32747,0.0,0.0,7.149999904632568,7.318749964237213,8.422499958674113,-0.6993007086280413,-2.305722431142416,-13.104778864381903,45.281921908793386,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-11-06,6.900000095367432,6.900000095367432,6.349999904632568,6.75,41290,0.0,0.0,7.119999885559082,7.291249966621399,8.40141662756602,-5.196627689693124,-2.3487067628497447,-13.214041276110935,37.46582533381578,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-11-07,6.5,7.050000190734863,6.5,7.0,68585,0.0,0.0,7.109999895095825,7.262499976158142,8.38291662534078,-1.547115284371501,-2.099829006030361,-13.36547527856501,44.79567303370788,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-11-08,6.800000190734863,7.349999904632568,6.800000190734863,7.099999904632568,27582,0.0,0.0,7.084999895095825,7.2474999785423275,8.367083291212717,0.2117150283534428,-2.2421536243893296,-13.380807549103748,47.449069808309545,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-11-11,7.150000095367432,7.150000095367432,6.550000190734863,6.550000190734863,42275,0.0,0.0,7.019999933242798,7.222499978542328,8.346833296616872,-6.695153090846604,-2.803738953286911,-13.470178187579918,36.93417294904992,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-11-12,6.699999809265137,6.900000095367432,6.400000095367432,6.900000095367432,23071,0.0,0.0,6.999999952316284,7.209999978542328,8.329499967892964,-1.428569394714967,-2.9126217316369534,-13.440182407898199,45.249104638433316,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-11-13,6.800000190734863,7.150000095367432,6.75,7.099999904632568,13000,0.0,0.0,6.9899999618530275,7.199999976158142,8.311999968687694,1.573675870956374,-2.916666875006972,-13.378248276210178,49.35797109014236,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-11-14,7.099999904632568,7.199999809265137,6.699999809265137,6.949999809265137,37397,0.0,0.0,6.964999961853027,7.189999973773956,8.29458330074946,-0.2153647188807691,-3.1293464915387004,-13.316923670845519,46.53713972326911,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-11-15,6.949999809265137,7.099999904632568,6.650000095367432,6.75,11165,0.0,0.0,6.919999980926514,7.1762499690055845,8.275833300749461,-2.456647129986738,-3.5708063290133576,-13.286678111850057,43.00782765385879,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-11-18,6.900000095367432,7.0,6.599999904632568,6.849999904632568,19339,0.0,0.0,6.9049999713897705,7.166249966621399,8.247083298365276,-0.7965252278796502,-3.645560738858751,-13.105643445581764,45.2438590377753,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-11-19,6.650000095367432,6.900000095367432,6.650000095367432,6.650000095367432,11458,0.0,0.0,6.8599999904632565,7.151249969005585,8.217083299160004,-3.0612229648362366,-4.07271427798836,-12.97094469351886,41.7184798385111,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-11-20,6.650000095367432,6.800000190734863,6.400000095367432,6.800000190734863,35804,0.0,0.0,6.865000009536743,7.138749969005585,8.190416634082794,-0.9468291145168715,-3.8347044042358385,-12.840209626222274,45.169257374182244,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-11-21,6.699999809265137,6.800000190734863,6.400000095367432,6.650000095367432,32326,0.0,0.0,6.830000019073486,7.126249969005585,8.161666631698608,-2.6354307936074055,-4.157164725074025,-12.686338580304554,42.461755770248836,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-11-22,6.75,6.75,6.300000190734863,6.449999809265137,20790,0.0,0.0,6.7650000095367435,7.101249969005584,8.130416631698608,-4.656322244309612,-4.7350813016926825,-12.658227853669171,39.096718743115986,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-11-25,6.5,7.050000190734863,6.5,6.699999809265137,12311,0.0,0.0,6.7799999713897705,7.0837499618530275,8.102083293596904,-1.1799433991477626,-4.287982948282939,-12.568783791061088,44.96761381516814,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-11-26,6.800000190734863,6.800000190734863,6.550000190734863,6.699999809265137,18195,0.0,0.0,6.759999942779541,7.062499952316284,8.072916626930237,-0.8875759470751405,-4.283186004660182,-12.516129192308629,44.96761381516814,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-11-27,6.75,7.099999904632568,6.75,7.0,35088,0.0,0.0,6.749999952316284,7.051249957084655,8.047083290417989,3.7037044362930303,-4.272292240409005,-12.375084206213144,51.47729235817647,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-11-28,6.949999809265137,7.199999809265137,6.949999809265137,7.199999809265137,7355,0.0,0.0,6.774999952316284,7.0437499523162845,8.02041662534078,6.2730606633222346,-3.8154392449951215,-12.177256103363547,55.27550583468039,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-11-29,7.599999904632568,8.0,7.099999904632568,7.449999809265137,47559,0.0,0.0,6.844999933242798,7.037499952316284,7.996666622161865,8.838566573012683,-2.735346648352408,-11.994581181955972,59.539003490309256,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-12-02,7.050000190734863,7.599999904632568,7.0,7.150000095367432,51606,0.0,0.0,6.874999952316284,7.033749949932099,7.971249957879384,4.000002108487228,-2.2569752798412566,-11.761016313640873,53.008701408956604,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-12-03,7.0,7.449999809265137,7.0,7.400000095367432,51392,0.0,0.0,6.9499999523162845,7.042499947547912,7.948749955495199,6.474822246598315,-1.3134539711829878,-11.401163868801405,57.21964960637449,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-12-04,7.400000095367432,7.75,7.150000095367432,7.349999904632568,54524,0.0,0.0,7.0049999237060545,7.046249949932099,7.925833284854889,4.925053314547199,-0.5854181517708117,-11.097676462657189,56.13616798031198,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-12-05,7.199999809265137,7.349999904632568,7.199999809265137,7.25,18455,0.0,0.0,7.064999914169311,7.051249945163727,7.90374995470047,2.618543355671658,0.19500044832497762,-10.786019477118572,53.93642898184958,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-12-06,7.199999809265137,7.400000095367432,7.0,7.150000095367432,20102,0.0,0.0,7.134999942779541,7.049999952316284,7.880416623751322,0.21023339464873106,1.2056736317470496,-10.53772549197702,51.75247154636476,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-12-09,7.400000095367432,7.400000095367432,6.900000095367432,7.050000190734863,33980,0.0,0.0,7.169999980926514,7.046249961853027,7.856666628519694,-1.6736372456188524,1.7562536064352616,-10.315019142149355,49.59004594424624,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-12-10,7.050000190734863,7.400000095367432,6.949999809265137,7.0,21233,0.0,0.0,7.2,7.037499964237213,7.832499965031942,-2.77777777777778,2.3090591344734768,-10.15001601460571,48.49886097039772,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-12-11,7.099999904632568,7.099999904632568,7.0,7.099999904632568,10522,0.0,0.0,7.209999990463257,7.033749961853028,7.809999962647756,-1.5256599996697215,2.505776144533244,-9.939180595483162,50.829223769101,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-12-12,7.099999904632568,7.199999809265137,7.0,7.150000095367432,22495,0.0,0.0,7.205000019073486,7.032499969005585,7.788333296775818,-0.763357717702365,2.4528979854697854,-9.704686471021084,51.99876588675423,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-12-13,7.0,7.099999904632568,6.900000095367432,7.099999904632568,31145,0.0,0.0,7.17000002861023,7.032499969005585,7.765833294391632,-0.976291822849958,1.9552088192058372,-9.44307323614131,50.70008580499221,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-12-16,6.949999809265137,7.150000095367432,6.900000095367432,7.0,23509,0.0,0.0,7.155000019073486,7.028749966621399,7.739999957879385,-2.1663175214576365,1.79619495716353,-9.18927642284968,48.112019841311906,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-12-17,7.0,7.099999904632568,6.75,7.099999904632568,12493,0.0,0.0,7.125,7.0212499618530275,7.717499955495199,-0.35087853147272474,1.4776576636731942,-9.021703889306933,50.81583284324851,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-12-18,6.949999809265137,7.150000095367432,6.900000095367432,7.0,44233,0.0,0.0,7.090000009536743,7.019999957084655,7.694999957084656,-1.2693936447910297,0.9971517504276141,-8.77192987348284,48.1157220923828,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-12-19,7.099999904632568,7.099999904632568,6.849999904632568,6.900000095367432,25991,0.0,0.0,7.0550000190734865,7.014999961853027,7.671249957879384,-2.197022300311922,0.5702075187166988,-8.55466839993008,45.511441327652285,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-12-20,7.099999904632568,7.150000095367432,6.400000095367432,6.800000190734863,147130,0.0,0.0,7.020000028610229,7.001249969005585,7.6491666277249655,-3.1339008116631026,0.26781017229281623,-8.470421553780241,43.004744286348405,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-12-23,6.5,6.949999809265137,6.449999809265137,6.800000190734863,35576,0.0,0.0,6.99500002861023,6.991249978542328,7.628333294391632,-2.787703174807695,0.05363919298282409,-8.351540123681927,43.004744286348405,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-12-27,6.949999809265137,7.0,6.699999809265137,6.949999809265137,16750,0.0,0.0,6.990000009536743,6.9874999761581424,7.609583294391632,-0.572248930143527,0.03577865312530969,-8.17499847451533,47.98833063366326,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2024-12-30,6.75,6.900000095367432,6.699999809265137,6.849999904632568,35462,0.0,0.0,6.965000009536743,6.978749978542328,7.592499963442484,-1.651114210290193,-0.1970262446406898,-8.083635006326409,45.1537352361478,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-01-02,6.75,7.099999904632568,6.699999809265137,7.0,14499,0.0,0.0,6.95,6.973749983310699,7.5758332967758175,0.7194244604316521,-0.3405625863780121,-7.947420301887551,49.931217655400715,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-01-03,7.0,7.449999809265137,6.849999904632568,7.400000095367432,55107,0.0,0.0,6.980000019073486,6.978749990463257,7.562083295981089,6.017193053671301,0.01791192709206816,-7.7139233024297384,59.949868309987956,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-01-07,7.349999904632568,8.25,7.25,7.400000095367432,24757,0.0,0.0,7.020000028610229,6.988749992847443,7.549166631698609,5.413106342001427,0.4471477130355071,-7.423556349889029,59.949868309987956,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-01-08,7.550000190734863,7.550000190734863,6.800000190734863,7.150000095367432,17523,0.0,0.0,7.025000047683716,6.989999997615814,7.533333297570547,1.7793600972989414,0.5007160240320453,-7.2123889716913805,52.35607815964893,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-01-09,7.050000190734863,7.199999809265137,6.800000190734863,6.949999809265137,21408,0.0,0.0,7.020000028610229,6.9949999928474424,7.515416626135508,-0.9971541176610329,0.35739865315725533,-6.924654469298108,47.20462022703235,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-01-10,6.949999809265137,8.0,6.900000095367432,7.25,50764,0.0,0.0,7.0550000190734865,7.001249992847443,7.501249961058298,2.7639968873043643,0.7677204253662584,-6.665555351528559,54.445192075628476,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-01-13,7.300000190734863,7.449999809265137,7.0,7.150000095367432,60093,0.0,0.0,7.090000009536743,7.002499997615814,7.484999958674113,0.8462635507754988,1.249553901474049,-6.446225300230572,51.89056176972876,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-01-14,7.099999904632568,7.699999809265137,7.0,7.199999809265137,55378,0.0,0.0,7.12999997138977,7.018749988079071,7.472083290417989,0.981764911027374,1.585039836148188,-6.067026888207487,53.076099147396555,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-01-15,7.050000190734863,7.150000095367432,6.949999809265137,7.099999904632568,14776,0.0,0.0,7.144999980926514,7.023749983310699,7.456249956289927,-0.6298121261591665,1.7262857861387377,-5.800502605393217,50.400994235267795,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-01-16,7.0,7.199999809265137,6.849999904632568,7.0,27216,0.0,0.0,7.159999990463257,7.021249985694885,7.440416626135508,-2.2346367412900663,1.976143920969371,-5.633644747368598,47.8061557668079,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-01-17,6.949999809265137,7.050000190734863,6.75,7.0,21245,0.0,0.0,7.159999990463257,7.022499990463257,7.426249961058299,-2.2346367412900663,1.9579921706903363,-5.436794784880961,47.8061557668079,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-01-20,6.949999809265137,7.25,6.650000095367432,7.0,46853,0.0,0.0,7.119999980926513,7.028749990463257,7.412083295981089,-1.68539299505585,1.2982392400791947,-5.171734992855249,47.8061557668079,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-01-21,6.699999809265137,7.0,6.650000095367432,7.0,28175,0.0,0.0,7.07999997138977,7.032499992847443,7.399583295981089,-1.1299431032916616,0.6754351737026411,-4.960864530479966,47.8061557668079,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-01-22,6.949999809265137,7.199999809265137,6.800000190734863,6.800000190734863,29481,0.0,0.0,7.044999980926514,7.036249995231628,7.38374996582667,-3.4776407502478084,0.12435581027984163,-4.706280307477019,41.99059048625751,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-01-23,7.449999809265137,7.550000190734863,6.900000095367432,7.199999809265137,95391,0.0,0.0,7.0699999809265135,7.046249985694885,7.369166632493337,1.8387528810373057,0.33705865218868003,-4.381996810529355,54.03422085221739,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-01-24,7.300000190734863,7.400000095367432,7.050000190734863,7.400000095367432,10020,0.0,0.0,7.084999990463257,7.064999985694885,7.355833299954733,4.446014189529705,0.2830857014701723,-3.9537779392259655,58.656172294638836,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-01-27,7.0,7.349999904632568,7.0,7.199999809265137,19627,0.0,0.0,7.089999961853027,7.083749985694885,7.342499963442484,1.551478815288459,0.08822976771856203,-3.5240038002844734,52.925085280586686,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-01-28,7.0,7.199999809265137,6.949999809265137,7.199999809265137,13245,0.0,0.0,7.089999961853027,7.096249985694885,7.334999958674113,1.551478815288459,-0.08807502349067667,-3.254941708580255,52.9250852805867,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-01-29,7.150000095367432,7.25,7.0,7.050000190734863,30217,0.0,0.0,7.084999990463257,7.104999995231628,7.3258332967758175,-0.4939985853988018,-0.28149197440948115,-3.0144461742172144,48.779467636740456,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-01-30,7.349999904632568,7.400000095367432,7.0,7.099999904632568,19528,0.0,0.0,7.094999980926514,7.107499992847442,7.314583297570547,0.07047108836498665,-0.175870727168592,-2.8311018727735964,50.180314641795405,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-01-31,7.0,7.349999904632568,6.699999809265137,7.300000190734863,36215,0.0,0.0,7.125,7.110000002384186,7.303333302338918,2.4561430278577303,0.210970430531427,-2.647192616730452,55.43112216075658,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-02-03,7.449999809265137,7.449999809265137,6.949999809265137,7.050000190734863,29259,0.0,0.0,7.130000019073487,7.100000011920929,7.289583305517833,-1.1220172247491669,0.42253531129841937,-2.6007425342598025,48.54376437598384,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-02-04,7.300000190734863,7.300000190734863,7.0,7.300000190734863,18246,0.0,0.0,7.160000038146973,7.103750014305115,7.2820833086967465,1.9553093832681439,0.7918356322869574,-2.4489323567426635,54.61646631133457,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-02-05,7.300000190734863,7.349999904632568,7.0,7.150000095367432,27625,0.0,0.0,7.195000028610229,7.097500014305115,7.273333311080933,-0.6254333990807445,1.3737233407340876,-2.417506379199421,50.746673257687114,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-02-06,7.199999809265137,7.25,6.949999809265137,7.25,46439,0.0,0.0,7.200000047683716,7.0950000166893,7.263333312670389,0.6944437775714942,1.4799158667713581,-2.317576362459411,53.13087876991107,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-02-07,7.400000095367432,7.400000095367432,6.650000095367432,7.099999904632568,170976,0.0,0.0,7.17000002861023,7.091250014305115,7.254999975363414,-0.976291822849958,1.1105237320113246,-2.257063564636282,49.27756816098975,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-02-10,6.75,7.050000190734863,6.699999809265137,7.0,52695,0.0,0.0,7.150000047683716,7.087500011920929,7.245416645208994,-2.097902750816196,0.881834718273926,-2.179538334658608,46.8387199534202,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-02-11,6.949999809265137,7.0,6.75,7.0,29470,0.0,0.0,7.130000066757202,7.086250007152557,7.239166645208995,-1.8232828266483831,0.6173936787508981,-2.112351401077915,46.8387199534202,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-02-12,7.0,7.150000095367432,6.800000190734863,6.949999809265137,17278,0.0,0.0,7.12000002861023,7.085000002384186,7.23249997695287,-2.3876435205334667,0.49400178142929824,-2.039405116331954,45.53196738715017,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-02-13,6.949999809265137,7.050000190734863,6.900000095367432,7.050000190734863,8986,0.0,0.0,7.115000057220459,7.083750009536743,7.2266666452089945,-0.9135610114244797,0.4411511931059705,-1.9776287282740463,48.61943156584426,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-02-14,7.050000190734863,7.099999904632568,7.0,7.099999904632568,7058,0.0,0.0,7.0950000286102295,7.082500004768372,7.221666646003723,0.07047041581644989,0.1764916884354645,-1.9270709665387624,50.14121372002913,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-02-17,7.099999904632568,7.400000095367432,7.0,7.199999809265137,31929,0.0,0.0,7.1099999904632565,7.085000002384186,7.217499979337057,1.2658202380112273,0.35285798264865975,-1.835815411599643,53.131102735607875,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-02-18,7.150000095367432,7.349999904632568,7.099999904632568,7.300000190734863,16360,0.0,0.0,7.1099999904632565,7.092500007152557,7.212916648387909,2.672295366054244,0.24673927801270773,-1.669458377316266,55.97429629173337,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-02-19,7.25,7.300000190734863,7.099999904632568,7.300000190734863,19076,0.0,0.0,7.125,7.097500014305115,7.207499984900156,2.4561430278577303,0.38746017103851793,-1.526187593832727,55.97429629173337,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-02-20,7.25,7.400000095367432,7.199999809265137,7.349999904632568,42974,0.0,0.0,7.134999990463257,7.106250011920929,7.198333319028219,3.013313447185473,0.4045731362406142,-1.2792309417497332,57.470355136975606,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-02-21,7.349999904632568,7.650000095367432,7.25,7.599999904632568,34480,0.0,0.0,7.184999990463257,7.123750007152557,7.194166648387909,5.775920872931753,0.8597997297659516,-0.9788019193457372,64.04866804569909,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-02-24,7.650000095367432,8.0,7.300000190734863,7.650000095367432,33313,0.0,0.0,7.25,7.145000004768372,7.189583317438761,5.517242694723195,1.4695590645423937,-0.620109826980514,65.20776931472017,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-02-25,7.5,7.900000095367432,7.449999809265137,7.900000095367432,21403,0.0,0.0,7.340000009536743,7.172500002384186,7.189583317438761,7.629428952358172,2.3353085687958046,-0.23761203257967853,70.35436634158421,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-02-26,8.0,8.0,7.550000190734863,7.650000095367432,39441,0.0,0.0,7.410000038146973,7.190000009536743,7.187916652361552,3.2388671522932393,3.0598056789766854,0.028984158775783864,60.686806705204134,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-02-27,7.650000095367432,7.650000095367432,6.949999809265137,7.150000095367432,54310,0.0,0.0,7.42000002861023,7.197500014305115,7.183333321412404,-3.6388131024491273,3.0913513562055326,0.19721614268520643,46.827501237566395,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-02-28,7.0,7.150000095367432,6.75,7.150000095367432,34847,0.0,0.0,7.4250000476837155,7.2012500166893005,7.178749990463257,-3.703703037713409,3.10709988510136,0.3134254049233376,46.82750123756639,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-03-03,7.0,7.050000190734863,6.5,6.599999904632568,78786,0.0,0.0,7.365000057220459,7.181250011920929,7.170833321412404,-10.386967367880787,2.558747362847746,0.1452647138990063,36.2625457165013,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-03-04,6.199999809265137,6.75,6.199999809265137,6.75,97013,0.0,0.0,7.310000038146972,7.165000009536743,7.162916656335195,-7.660739195959401,2.0237268446229124,0.029085263748046486,40.22359169955335,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-03-05,6.300000190734863,6.849999904632568,6.300000190734863,6.300000190734863,43593,0.0,0.0,7.210000038146973,7.143750011920929,7.150833324591319,-12.62135704018646,0.9273844425615518,-0.09905576523550944,33.49788356222146,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-03-06,6.25,6.25,5.5,6.050000190734863,69214,0.0,0.0,7.0800000667572025,7.121250021457672,7.135833326975504,-14.548020710600106,-0.5792516001569321,-0.20436723854946678,30.451540562731594,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-03-07,6.0,6.199999809265137,5.900000095367432,6.0,19916,0.0,0.0,6.920000076293945,7.090000021457672,7.117916663487752,-13.29479864379796,-2.397742519735217,-0.3922024287426961,29.866531548690773,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-03-10,6.0,6.150000095367432,5.400000095367432,5.949999809265137,90056,0.0,0.0,6.750000047683716,7.060000014305115,7.103333330154419,-11.851855300254428,-4.390934362510921,-0.6100419878277294,29.261149750184998,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-03-11,5.900000095367432,6.150000095367432,5.900000095367432,5.949999809265137,7175,0.0,0.0,6.5550000190734865,7.028750014305115,7.089999993642171,-9.229598902333235,-6.7401742026311755,-0.8638925161069226,29.261149750184998,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-03-12,6.0,6.150000095367432,6.0,6.150000095367432,16948,0.0,0.0,6.405000019073486,7.005000019073487,7.079583326975505,-3.981263433984212,-8.5653104691834,-1.0534985529138645,35.341115075211576,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-03-13,6.150000095367432,6.25,5.900000095367432,6.199999809265137,26841,0.0,0.0,6.309999990463257,6.985000014305115,7.068749992052714,-1.743267533508255,-9.663565103213658,-1.1847919058073662,36.80348688983751,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-03-14,6.050000190734863,6.900000095367432,6.050000190734863,6.650000095367432,82715,0.0,0.0,6.259999990463257,6.976250016689301,7.062916660308838,6.230033634158421,-10.266977595593008,-1.2270659245715594,48.16599738913108,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-03-17,6.599999904632568,7.099999904632568,6.599999904632568,6.949999809265137,51657,0.0,0.0,6.294999980926514,6.975000011920929,7.059999990463257,10.405080704102213,-9.749104370354566,-1.2039657033590228,54.092005431609,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-03-18,8.0,8.0,6.849999904632568,7.0,42120,0.0,0.0,6.3199999809265135,6.975000011920929,7.057916657129923,10.759494005153435,-9.390681431899052,-1.1748034049854086,55.01510741052816,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-03-19,7.0,7.0,6.75,6.849999904632568,9542,0.0,0.0,6.374999952316284,6.976250004768372,7.054583323001862,7.450979699908832,-8.618527891648435,-1.1103890144451174,51.65917370351191,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-03-20,6.699999809265137,6.900000095367432,6.550000190734863,6.599999904632568,25612,0.0,0.0,6.429999923706054,6.961250007152557,7.048749987284342,2.64385665542172,-7.631532884189668,-1.2413545705214575,46.56129375404979,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-03-21,6.550000190734863,6.650000095367432,5.900000095367432,6.25,91340,0.0,0.0,6.454999923706055,6.932500004768372,7.041249986489614,-3.1758315434395334,-6.887848261577767,-1.5444698303554958,40.53095648737854,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-03-24,6.25,6.300000190734863,6.050000190734863,6.25,19076,0.0,0.0,6.484999942779541,6.908750009536743,7.031249988079071,-3.6237462583356224,-6.133527283115813,-1.7422219200002358,40.53095648737854,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-03-25,6.550000190734863,6.949999809265137,6.5,6.5,18566,0.0,0.0,6.539999961853027,6.891250014305115,7.023749987284343,-0.6116202153874915,-5.097044102636668,-1.8864562835964167,46.293148253924315,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-03-26,6.550000190734863,6.650000095367432,6.400000095367432,6.650000095367432,25776,0.0,0.0,6.589999961853027,6.881250011920929,7.016249986489614,0.9104724409973012,-4.232516614907849,-1.9241043980564958,49.457533808154494,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-03-27,6.550000190734863,6.900000095367432,6.550000190734863,6.800000190734863,12008,0.0,0.0,6.65,6.873750019073486,7.010833323001862,2.255641965937788,-3.2551375661410087,-1.955306846029536,52.47319796491493,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-03-28,6.849999904632568,6.900000095367432,5.949999809265137,6.599999904632568,90469,0.0,0.0,6.644999980926514,6.856250011920929,7.003333322207133,-0.6772020530189821,-3.08113080221865,-2.1001900597792664,48.33235933979411,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-03-31,6.550000190734863,6.550000190734863,6.150000095367432,6.5,48112,0.0,0.0,6.6,6.842500007152557,6.99333332379659,-1.5151515151515098,-3.544026407001372,-2.156815779547996,46.36234312032775,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-04-01,6.360000133514404,6.480000019073486,6.199999809265137,6.440000057220459,23400,0.0,0.0,6.5440000057220455,6.821000003814698,6.9861666560173035,-1.5892412654439099,-4.060988094674354,-2.3641957075321844,45.17262769075562,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-04-02,6.420000076293945,6.5,6.199999809265137,6.300000190734863,16840,0.0,0.0,6.489000034332276,6.799750006198883,6.979916656017304,-2.9126189335405135,-4.570020538745056,-2.581214915554924,42.43624914678527,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-04-03,6.900000095367432,6.900000095367432,6.039999961853027,6.079999923706055,10626,0.0,0.0,6.437000036239624,6.770500004291534,6.970583323637644,-5.5460635470513715,-4.925780486530076,-2.8703956334273473,38.49045736669448,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-04-04,6.019999980926514,6.21999979019165,6.0,6.0,10793,0.0,0.0,6.412000036239624,6.74300000667572,6.961833322048188,-6.425452805849403,-4.908793861907146,-3.1433288510286608,37.13817080957312,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-04-07,5.980000019073486,6.0,5.21999979019165,5.639999866485596,54390,0.0,0.0,6.351000022888184,6.70900000333786,6.948833322525024,-11.19508981011235,-5.3361153714646665,-3.4514185051716653,31.734965585335203,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-04-08,5.699999809265137,6.440000057220459,5.699999809265137,5.820000171661377,20782,0.0,0.0,6.283000040054321,6.679500007629395,6.937333325544993,-7.369089056840769,-5.936072567141064,-3.716605586273213,36.69435970299291,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-04-09,5.940000057220459,6.260000228881836,5.699999809265137,6.019999980926514,53279,0.0,0.0,6.2200000286102295,6.656250011920929,6.926249992847443,-3.2154348354304267,-6.553990347859577,-3.8982130475413905,41.75740753543481,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-04-10,6.079999923706055,6.300000190734863,5.840000152587891,5.920000076293945,39433,0.0,0.0,6.1320000171661375,6.628000009059906,6.915166660149892,-3.4572723463586446,-7.483403609169869,-4.152707594812499,40.03337096756405,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-04-11,5.820000171661377,5.940000057220459,5.5,5.900000095367432,30342,0.0,0.0,6.062000036239624,6.598000013828278,6.904333329200744,-2.6723843600087487,-8.123673483863136,-4.4368268559236546,39.68050899424772,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-04-14,5.900000095367432,6.900000095367432,5.900000095367432,6.28000020980835,19691,0.0,0.0,6.040000057220459,6.5750000238418576,6.8974999984105425,3.973512422421009,-8.136881592112779,-4.67560673639727,48.89704170048503,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-04-15,6.239999771118164,6.340000152587891,5.760000228881836,6.019999980926514,49245,0.0,0.0,5.998000049591065,6.543000018596649,6.888083330790201,0.3667877818198549,-8.329511958682163,-5.009859718900419,43.948997610513544,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-04-16,6.320000171661377,6.320000171661377,5.920000076293945,6.300000190734863,26396,0.0,0.0,5.998000049591065,6.518000018596649,6.878916664918264,5.035013982108727,-7.9779068352556175,-5.246707641658905,49.83622119798733,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-04-17,6.380000114440918,6.380000114440918,6.039999961853027,6.340000152587891,2196,0.0,0.0,6.024000072479248,6.492750024795532,6.8729999979337055,5.245685197652873,-7.219590320374998,-5.53251816168328,50.6339249759339,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-04-22,6.5,6.659999847412109,6.340000152587891,6.519999980926514,50453,0.0,0.0,6.076000070571899,6.465750026702881,6.8681666652361555,7.307437544397913,-6.027915624967784,-5.8591565718715435,54.16604864789797,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-04-23,6.320000171661377,6.760000228881836,6.300000190734863,6.340000152587891,16422,0.0,0.0,6.146000099182129,6.433000028133392,6.859750000635783,3.1565253868378202,-4.461369931542492,-6.221071795077636,50.29095776579249,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-04-24,6.71999979019165,6.71999979019165,6.320000171661377,6.679999828338623,11780,0.0,0.0,6.232000064849854,6.402500021457672,6.855416667461395,7.188699596067205,-2.663021570267799,-6.6066975644741,56.605990575323915,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-04-25,6.679999828338623,6.679999828338623,6.260000228881836,6.559999942779541,19866,0.0,0.0,6.286000061035156,6.3752500176429745,6.850916667779287,4.35889085402369,-1.3999444156829393,-6.943109560410093,53.9985791703696,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-04-28,6.539999961853027,6.539999961853027,6.199999809265137,6.380000114440918,16013,0.0,0.0,6.332000064849853,6.356000018119812,6.844083336989085,0.7580551026447727,-0.3775952360217008,-7.131463701375605,50.258886036609155,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-04-29,6.119999885559082,6.300000190734863,6.119999885559082,6.260000228881836,11887,0.0,0.0,6.368000078201294,6.333750021457672,6.836250007152557,-1.6959775124557392,0.5407547918308756,-7.350520902090106,47.87829008700016,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-04-30,6.599999904632568,6.599999904632568,6.119999885559082,6.239999771118164,17156,0.0,0.0,6.364000034332276,6.324750018119812,6.828250006834666,-1.948464213468878,0.6205781430098547,-7.373777881754191,47.474664653132635,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-05-02,6.239999771118164,6.460000038146973,6.199999809265137,6.360000133514404,39257,0.0,0.0,6.398000049591064,6.3150000214576725,6.8229166746139525,-0.593934288560826,1.3143313990715262,-7.444274602474439,50.187986404138584,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-05-05,6.380000114440918,6.380000114440918,6.159999847412109,6.199999809265137,49398,0.0,0.0,6.388000011444092,6.312500011920929,6.815416673819224,-2.9430213187563092,1.1960395941478594,-7.379103669922365,46.72237130222109,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-05-06,6.099999904632568,6.420000076293945,5.940000057220459,5.960000038146973,21548,0.0,0.0,6.35,6.310250008106232,6.808833340803782,-6.141731682724835,0.6299273696399387,-7.3225956304386886,42.03367050775277,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-05-07,6.099999904632568,6.099999904632568,5.800000190734863,6.059999942779541,26233,0.0,0.0,6.303999996185302,6.31175000667572,6.801000006993612,-3.870559225149294,-0.12278703184094894,-7.193795027419285,44.53141589114879,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-05-08,6.059999942779541,6.400000095367432,5.78000020980835,6.400000095367432,57314,0.0,0.0,6.309999990463257,6.323000013828278,6.795166675249735,1.4263091131568688,-0.2055989773302251,-6.948566297001165,52.09033514510964,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-05-09,6.239999771118164,6.360000133514404,5.71999979019165,6.099999904632568,33327,0.0,0.0,6.251999998092652,6.326750016212463,6.79141667286555,-2.4312235045818182,-1.1814915703680786,-6.84196948936468,46.11841366838798,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-05-12,6.199999809265137,6.300000190734863,6.019999980926514,6.019999980926514,47637,0.0,0.0,6.1980000019073485,6.32350001335144,6.784083338578542,-2.8718944970322324,-1.9846605705560345,-6.78917551923245,44.64841903962545,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-05-13,6.0,6.28000020980835,5.900000095367432,6.260000228881836,19017,0.0,0.0,6.186000013351441,6.3250000238418576,6.777083341280619,1.1962530774438753,-2.197628616070534,-6.670765204922718,49.81628236424572,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-05-14,6.21999979019165,6.239999771118164,6.019999980926514,6.21999979019165,27899,0.0,0.0,6.181999969482422,6.314250016212464,6.7710000077883405,0.6146849061277199,-2.0944695948129537,-6.745679974161871,48.99522687339281,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-05-15,6.199999809265137,6.199999809265137,5.920000076293945,6.019999980926514,21330,0.0,0.0,6.159999990463257,6.291000020503998,6.764916674296061,-2.2727274310631116,-2.0823403213126332,-7.005506151949427,45.001505613520635,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-05-16,5.920000076293945,6.099999904632568,5.519999980926514,5.840000152587891,71426,0.0,0.0,6.107999992370606,6.262000024318695,6.756500009695689,-4.387685660076439,-2.459278686522276,-7.318877890437031,41.7065087426346,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-05-19,4.199999809265137,4.289999961853027,3.700000047683716,3.9000000953674316,1067897,0.0,0.0,5.878000020980835,6.188250029087067,6.733583343029022,-33.650900281612174,-5.013533820513749,-8.098708906699946,22.545886377637302,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-05-20,3.880000114440918,3.950000047683716,3.6500000953674316,3.7100000381469727,352071,0.0,0.0,5.653000020980835,6.116000032424926,6.707833341757456,-34.37112994202216,-7.570307537433363,-8.823017495802437,21.503905405481916,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-05-21,3.619999885559082,3.799999952316284,3.549999952316284,3.5999999046325684,308741,0.0,0.0,5.407000017166138,6.049750030040741,6.682416673501333,-33.419643181000694,-10.624406127244148,-9.46763236075039,20.901627755488292,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-05-22,3.6700000762939453,3.740000009536743,3.5999999046325684,3.7100000381469727,119915,0.0,0.0,5.138000011444092,5.986250030994415,6.659583342075348,-27.79291494971725,-14.169973107678816,-10.110742316667215,23.217560772568618,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-05-23,3.759999990463257,3.990000009536743,3.75,3.890000104904175,91896,0.0,0.0,4.917000031471252,5.92100003361702,6.63616667787234,-20.886717917302537,-16.95659510970217,-10.776803521827965,26.984904470000984,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-05-26,3.890000104904175,3.9600000381469727,3.8499999046325684,3.9000000953674316,59782,0.0,0.0,4.705000042915344,5.85225003361702,6.612833346923193,-17.109456752504364,-19.603571004511757,-11.501625300447884,27.198614343296953,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-05-27,3.9200000762939453,3.9200000762939453,3.5999999046325684,3.890000104904175,66519,0.0,0.0,4.468000030517578,5.779500031471253,6.586916681130727,-12.936435131278342,-22.692274311136465,-12.257884663585441,27.113151642067123,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-05-28,3.9000000953674316,3.9000000953674316,3.75,3.7899999618530273,18338,0.0,0.0,4.225000047683716,5.709250032901764,6.558500015735627,-10.295859903461308,-25.997284698769235,-12.948844717485414,26.225704058194708,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-05-30,3.799999952316284,3.859999895095825,3.640000104904175,3.6700000762939453,103293,0.0,0.0,3.990000057220459,5.6385000348091125,6.527000017960867,-8.020049532265773,-29.236498490940644,-13.612685471224111,25.16140779163119,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-06-02,3.680000066757202,3.859999895095825,3.6700000762939453,3.8499999046325684,32499,0.0,0.0,3.7910000324249267,5.5737500309944155,6.499500016371409,1.5563142100503282,-31.98474974040821,-14.243403077854422,29.76567716847856,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-06-03,3.8299999237060547,3.890000104904175,3.7200000286102295,3.7200000286102295,57531,0.0,0.0,3.7730000257492065,5.5092500269413,6.468833349148432,-1.404717645832847,-31.51517888463029,-14.83394718049822,28.406403519529704,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-06-04,3.7100000381469727,3.9000000953674316,3.7100000381469727,3.8299999237060547,110019,0.0,0.0,3.7850000143051146,5.453000026941299,6.439500015974045,1.1889011685829973,-30.58866686952504,-15.319512176187592,31.266581703863565,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-06-05,3.7799999713897705,4.070000171661377,3.7699999809265137,3.930000066757202,81311,0.0,0.0,3.8180000305175783,5.40125002861023,6.411833349863688,2.9334739482555956,-29.31265891610706,-15.761222510172423,33.85370695262496,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-06-09,3.930000066757202,3.930000066757202,3.819999933242798,3.930000066757202,32688,0.0,0.0,3.840000033378601,5.35850003361702,6.3850000162919365,2.3437508488617143,-28.338154160902786,-16.076742052556057,33.85370695262496,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-06-10,3.9200000762939453,3.940000057220459,3.8399999141693115,3.869999885559082,51322,0.0,0.0,3.838000011444092,5.309750026464462,6.358500013748805,0.8337643048351564,-27.71787763425741,-16.49366965505482,32.989638061545875,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-06-11,3.8299999237060547,3.880000114440918,3.7100000381469727,3.880000114440918,97227,0.0,0.0,3.8360000133514403,5.256250029802322,6.332500014702479,1.1470307856186805,-27.02021419069166,-16.99565704542241,33.29522943848164,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-06-12,3.809999942779541,3.880000114440918,3.700000047683716,3.799999952316284,56221,0.0,0.0,3.8269999980926515,5.2032500267028805,6.305000015099844,-0.7055146535099007,-26.449815433572603,-17.474226578245556,32.036562980285865,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-06-13,3.759999990463257,4.050000190734863,3.759999990463257,3.869999885559082,48261,0.0,0.0,3.834999990463257,5.152500021457672,6.277666680018107,0.9126439421867413,-25.570112091366603,-17.923325909320013,34.37429159901605,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-06-16,3.859999895095825,3.9800000190734863,3.809999942779541,3.950000047683716,60208,0.0,0.0,3.862999987602234,5.094250017404557,6.2514166812102,2.2521372084052924,-24.1694071864503,-18.510470871086294,37.03969829829939,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-06-17,3.9100000858306885,3.9700000286102295,3.9000000953674316,3.950000047683716,36460,0.0,0.0,3.8730000019073487,5.042500019073486,6.226000014940897,1.9881240830995777,-23.19286093688548,-19.00899442703657,37.03969829829939,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-06-18,3.930000066757202,4.050000190734863,3.9000000953674316,3.9700000286102295,29398,0.0,0.0,3.8980000019073486,4.98425001502037,6.199916682640711,1.84710176161237,-21.79365019490464,-19.607790392153397,37.77248906984227,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-06-19,3.9700000286102295,4.139999866485596,3.869999885559082,4.039999961853027,125020,0.0,0.0,3.919000005722046,4.9267500102519985,6.175250015656153,3.0875212032230666,-20.45466082981562,-20.217804983422923,40.387671585504044,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-06-23,4.039999961853027,4.039999961853027,4.0,4.0,78567,0.0,0.0,3.9259999990463257,4.863750010728836,6.151083348194758,1.884870121539731,-19.280390842743746,-20.928562735924125,39.36948826413599,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-06-24,4.0,4.039999961853027,4.0,4.0,40558,0.0,0.0,3.9329999923706054,4.805250006914139,6.127750013271967,1.703534395102059,-18.15202150332402,-21.582146848246964,39.36948826413599,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-06-25,4.070000171661377,4.070000171661377,4.0,4.03000020980835,48384,0.0,0.0,3.949000024795532,4.739000016450882,6.10466668009758,2.051156862603753,-16.670183349081196,-22.37086372134028,40.67050210569715,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-06-26,4.0,4.150000095367432,4.0,4.150000095367432,50824,0.0,0.0,3.9760000228881838,4.678750020265579,6.081333349148433,4.376259342998027,-15.020037282041102,-23.063746852148086,45.690544186466916,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-06-27,4.139999866485596,4.170000076293945,4.03000020980835,4.099999904632568,41088,0.0,0.0,4.006000018119812,4.62175001502037,6.058416682481766,2.346477436035432,-13.322875423798635,-23.713566477122537,44.019242831326274,,,0.0,0.0,-0.63978,,18.98148,-6.3076925,Initiator Pharma A/S,Healthcare,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
